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The Expression and Significance of MGMT, Ku80 and Ki67 Gene 
in Different Grades of Spinal gliomas 
1. Introduction 
1.1 Epidemiology, magnetic resonance imaging, pathological classification, 
treatment，prognostic immunophenotype and prognostic factors in spinal glioma 
1.11 Epidemiology of spinal glioma 
Primary tumors of the central nervous system (CNS) account for approximately 2-3% 
of all cancers. In Western countries, the annual incidence is approximately 15 patients 
per 100,000 populations and the prevalence has been estimated to approximately 69 
patients per 100,000 populations (Ohgaki H, 2005). Primary CNS tumors comprise a 
heterogeneous group of benign and malignant neoplasms, the most common of which 
are tumors of glial cells, collectively referred to as gliomas. They are histologically 
classified according to the World Health Organization (WHO) classification of tumors 
of the nervous system. (Riemenschneider MJ, 2009). Gliomas are the most common 
primary human CNS tumors, that account for over 60% with 30-40% of them being 
glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% 
being low grade gliomas (LGGs) (Ghosh A, 2004). But most CNS gliomas are brain 
glioma. Gliomas arising from the spinal cord are infrequent and comprise 5% of all 
primary central nervous system malignancies (Raco A, 2005; Santi M, 2003).  
Spinal neoplasms in the adult population are mostly extradural (55%) and intradural 
extramedullary tumors (40%), whereas intramedullary tumors are rare (5%). In 
contrast, the rate of intramedullary tumors in children is higher with up to 35% of all 
spinal neoplasms. According to the literature, most spinal cord tumors in children are 
malignant gliomas, in more detail astrocytomas - in contrast to the adult population, 
where most spinal cord tumors are benign ependymoma (Stecco A, 2005; Costantini S, 
1996; Koeller KK, 2000). 
Spinal gliomas include astrocytomas and ependymomas. Spinal cord astrocytomas 
constitute approximately 1% of all primary central nervous system tumors, and 6 to 
8% of all spinal cord tumors (Johnson DL, 1987). Few spinal cord astrocytomas are 
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anaplastic in nature; the majority of intramedullary spinal cord tumors are 
slow-growing low-grade ependymoma. Glioblastomas represent approximately 7.5% 
of all intramedullary gliomas and approximately 1.5% of all spinal cord tumors 
(Cohen AR, 1989). Unlike their intracranial counterpart, intramedullary glioblastomas 
have received scant attention in the literature, with fewer than 200 cases ever reported 
(Ciappetta P, 1991). Nonetheless, they are regarded as particularly threatening 
because of the densely packed essential fiber tracts and interneuronal networks within 
the cord’s parenchyma. 
The incidence of spinal glioma is increasing, but they are still regarded as rare tumors. 
The increase may be explained by improvement in diagnostic techniques especially 
due to the use of magnetic resonance imagine (MRI). 
 
1.12 Magnetic Resonance Imaging characters of spinal glioma 
MRI has become the best method for studying and identifying spinal cord neoplasm 
during the last 2 decades (Brotchi JF, 1999; Brotchi J, 1991). 
Although MRI is not sufficiently specific to make a histologic diagnosis in glial 
tumors, typical imaging patterns can be identified for the more common tumor types. 
Ependymomas usually are enhanced brightly and homogeneously with contrast agents. 
They often have rostral and caudal cysts with a hemosiderin ‘cap’ at their poles, 
which is dark on T2-weighted images. On axial view, ependymomas are usually 
located in the center of the cord. Astrocytomas and gangliogliomas enhance less 
frequently, and if they do, enhancement is usually inhomogeneous. On axial views, 
they are eccentric and often asymmetrically enlarge the cord (Dillon WP, 1989; Patel 
U, 1998; Kothbauer KF, 2007). 
 
1.13 Pathological classification of spinal glioma 
Tumor resection and not only tumor biopsy is the standard in spinal glioma surgery to 
harvest tissue for histological diagnosis. 
Surgery is indicated for any newly diagnosed intramedullary tumor in a child or in an 
adult for three reasons: first to receive the histological diagnosis, second to reduce the 
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cell load for further treatments, and third to decompress the cord in order to prevent 
short- and long-term neurologic dysfunctions (Kothbauer, 2007). 
Spinal gliomas can occur throughout the entire spinal axis from medulla oblongata to 
sacral myelon. According to the latest World Health Organization (WHO) 
classification of tumors of the nervous system (Louis DN, 2007; Kleihues and 
Webster, 2000), four histological malignancy grades have been defined for spinal 
glioma that reach from benign tumors of WHO grade I to highly malignant tumors of 
WHO grade IV. Pilocytic astrocytoma, the most common glioma in childhood, is the 
prototype of a WHO grade I lesion. On the other end of the spectrum, WHO grade IV 
is assigned to glioblastoma, the most common and most malignant type of glioma, 
which preferentially manifests in adults with a peak incidence between 50 and 60 
years. The histological diagnosis and grading is: (i) grade I (ependymoma I and 
pilocytic astrocytoma I), (ii) grade II (ependymoma II, ganglioglioma II and 
astrocytoma II), (iii) grade III (ependymoma III and astrocytoma III) and (iiii) grade 
IV (glioblastoma IV).  
Pilocytic astrocytoma I or, less frequently, fibrillary astrocytomas I are the benign 
spinal tumors. The latter are, like in the brain, poorly demarcated from normal tissue. 
The pilocytic tumors frequently have large areas of good demarcation as well as 
cystic components and smaller areas of diffuse growth next to the normal cord tissue 
(Kothbauer, 2007). 
Gangliogliomas are also low-grade tumors and occur primarily in children and young 
adults. Histologically, they are characterized by well-differentiated neuronal and 
astrocytic cells. The neurons have characteristic nuclear and nucleolar features, 
abundant cytoplasm, and argyrophilic neuritic processes. They express neuronal 
markers like synaptophysin and neurofilament proteins. Most frequently, 
intramedullary gangliogliomas grow slowly and thus have an indolent course (Lang 
FF, 1993). 
Ependymomas are glial tumors derived from the primitive ependymal or 
subependymal cells of the cerebral ventricles and the central canal of the spinal cord 
(Fakhrai N, 2004). They constitute 5% of all neuroepithelial tumors. Concerning 
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malignancies in the pediatric age, ependymomas are the third most common tumor of 
the central nervous system, usually located intracranially with a high recurrence rate. 
In adults, however, more than 50% of all ependymomas are intraspinal and the 
frequency of recurrence is rare (Fakhrai N, 2004). According to the WHO, 
ependymomas are divided into 3 groups: (i) subependymomas and myxopapillar      
ependymomas, WHO grade I (indolent subtypes) (ii) atypical ependymomas, WHO 
grade II, and (iii) anaplastic tumors, WHO grade III (N. Fakhrai et al, 2004). 
Ependymomas are the most common intramedullary neoplasm in adults, while in 
children they account for only 12% of all intramedullary tumors. Ependymomas 
typically have a central location in the spinal cord. Most often they are well 
circumscribed and clearly delineated from the surrounding spinal cord tissue. 
Frequently, they have rostral and caudal capping cysts at the tumor poles. Practically 
all of them are histologically benign. Myxopapillary ependymomas are a subgroup of 
ependymomas with characteristic microcystic histologic features. They are typically 
located in the conus-cauda region (Schweitzer JS, 1992). They may grossly enlarge 
the filum and displace the nerve roots laterally and anteriorly. In spite of their benign 
histology, a small percentage of them tend to disseminate in the subarachnoidal space. 
Spinal cord astrocytomas account for approximately 3% of all central nervous system 
astrocytomas. (Roonprapunt C, 2006). Few spinal cord astrocytomas are anaplastic 
(grade III) in nature; most are slow-growing lesions. Glioblastomas (grade IV) 
represent approximately 7.5% of all intramedullary gliomas and approximately 1.5% 
of all spinal cord tumors. In adults, spinal cord astrocytomas are typically low grade 
(WHO Grade I or II), with high-grade lesions accounting for 10 to 30% of the cases. 
Patients with WHO Grade III or IV lesions have a median survival of 10 months 
(Roonprapunt C, 2006; Santi M, 2003). 
 
1.14 Prognostic immunophenotype 
Gliomas are the most common primary human brain tumors. Over the past 20 years 
the cytogenetic and molecular genetic alterations associated with brain glioma 
formation and progression have been intensely studied. Genetic profiles in order to 
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define immunophenotypic profiles that better identify risk groups and prognostic 
assessment, as additional aids to the definition of brain tumors have been incorporated 
in the WHO classification. MGMT promoter hypermethylation in glioblastomas or 
detection of losses of chromosome arms 1p and 19q in oligodendroglial tumors have 
been identitified as prognostic markers.  
The most common chromosomal abnormality has been studied in diffuse 
astrocytomas of WHO grade II: trisomy 7 or at least a gain of 7q, which has been 
detected by comparative genomic hybridization in 50% of the cases (Nishizakib T, 
1998; Schrock, E 1996). Very popular molecular alterations are mutations of the TP53 
tumor suppressor gene at 17q13.1, which can be found in about 60% of cases as well 
as the just recently identified codon 132 mutations of the isocitrate dehydrogenase 1 
(IDH1) gene in about 70% of diffuse astrocytomas (Balss J, 2008; Parsons DW,  
2008). In addition, about 25% of anaplastic astrocytomas carry mutations in the 
retinoblastoma gene (RB1). In contrast to glioblastomas, allelic losses on 10q and 
mutation of the PTEN tumor suppressor gene on 10q23 are rare in anaplastic 
astrocytomas (<10% of cases) (Smith JS, 2000). Glioblastomas usually carry multiple 
chromosomal and genetic aberrations, for example, TP53 mutation is found in 30% of 
primary glioblastomas. In contrast, secondary glioblastomas arise from a lower-grade 
precursor lesion and carry TP53 and IDH1 mutations in more than two thirds of the 
cases (Ohgaki H, 2007; Parsons DW, 2008). Also epigenetic silencing of various 
genes has been described as overrepresented in either primary (NDRG2) or secondary 
(MGMT and EMP3) glioblastomas (Tepel M, 2007; Mueller W, 2008), and this 
epigenetic silencing of MGMT by means of promoter hypermethylation is present in 
about 40% of primary glioblastomas and has been identified as the main mechanism 
reducing MGMT expression and thereby diminishing its DNA repair activity.  
Suri VS et al analyzed the expression of p53 and Ki67 and could show in 4 out of 11 
cases of clear cell ependymomas in brain higher Ki67 indices as compared to classical 
grade II ependymomas, thus further highlighting the importance of differentiating the 
various subtypes (Suri VS, 2004). Benadiba M et al（2009） found that Ku80 
expression, a critical protein involved in DNA repair as a heterodimer with Ku70, was 
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decreased by 71% after using Gamma-linolenic acid (GLA) in C6 glioma cells in 
vitro. It is indicated that reduced Ku80 is responsible for the increase in micronucleus 
formation in GLA-treated cells in a similar manner to that found in Ku80 null cells 
exposed to radiation. The decreased expression of Ku80 and E2F1 could make cells 
more susceptible to radiotherapy and chemotherapy (Benadiba M, 2009). 
Integrative analysis of the different platforms will not only expand our knowledge of 
the molecular basis of brain gliomas but also pave the way to a molecularly refined 
brain glioma classification and facilitate the detection of “genes in context”, i.e. 
pathways of gliomagenesis that can be specifically targeted with individualized 
therapies (Riemenschneider MJ, 2009). 
Although there have been many molecular and genetic research efforts on brain 
glioma for the past decades as mentioned above, similar studies for the spinal glioma 
are scarce. Richard A. R and Robert W (2007) have reported one case of a 
28-year-old woman with a high-grade spinal cord astrocytoma. They treated the 
patient using temozolomide (TMZ) that led to functional recovery and regression of 
the residual tumor as demonstrated on serial magnetic resonance images, in the same 
time, genetic testing revealed that this tumor did not express the DNA repair enzyme 
MGMT. This is the first and only one case report in the literature correlating MGMT 
expression with the clinical response of a spinal glioma treated using TMZ until  
now . Another correlation molecular and genetic studies of spinal glioma was on 
selected candidate genes revealed frequent NF2 gene mutations in intramedullary 
spinal ependymomas, while deletions of the CDKN2A gene were frequent in 
intracranial supratentorial ependymomas but rare in ependymomas from spinal or 
other locations (Taylor MD, 2005). These immunophenotypes in spinal glioma on the 
other hand were seldom studied maybe due to its rare incidence. There is still 
uncertainty with regard to many proteins expressions in spinal glioma. 
 
1.15 Prognostic factors in spinal glioma 
Spinal gliomas are uncommon tumors; and malignant spinal cord gliomas grades 
III-IV (astrocytoma III, ependymoma III and glioblastoma IV) are even rarer. As such, 
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there is no consensus regarding the treatment of most glioma (Richard AR, 2007). 
Prognostic factors are important not only for discrimination of patients with spinal 
glioma into specific risk groups, for the identification and assessment of appropriate 
therapies and to predict survival, but also for comparing results of clinical trials. Since 
traditional prognostic markers in brain glioma, such as KPS (Karnofsky performance 
score), p53, PTEN (Phosphatase and Tensin homolog) (Umesh S, 2009), 1p/19q 
codeletion (Ducray F,2009) and MGMT (Richard AR, 2007; Ducray F, 2009) have 
not been described before and are not applicable to spinal glioma several studies were 
initiated to search for new markers predicting survival and selecting an adequate 
therapy (Taylor MD, 2005; Richard AR, 2007). 
Because spinal gliomas are rare tumors, it is difficult to identify prognostic factors. 
Prognostic pathobiological biomarkers in spinal glioma have been described clinically 
by Rudà R (Rudà R, 2008): If compared with intracranial ependymomas, spinal 
ependymomas are less frequent and exhibit a better prognosis. There is evidence that 
intracranial and spinal ependymomas share some similar molecular profiles with the 
radial glia of their corresponding locations. The majority of studies have shown a 
major impact of the extent of resection; thus, a complete resection must be achieved, 
whenever possible, at first surgery or at reoperation. Involved field radiotherapy is 
recommended for anaplastic or incompletely resected grade II tumors. Craniospinal 
irradiation is reserved for metastatic disease. Chemotherapy is not advocated as 
primary treatment, but utilized as salvage treatment for patients failing surgery and 
radiotherapy. The extent of resection and radiotherapy is considered as statistically 
significant prognostic factors for spinal ependymoma (Rudà R, 2008). 
 
1.16 Treatment of spinal glioma 
Because primary spinal cord gliomas are infrequent, there is no consensus regarding 
the management of malignant spinal cord glioma. Surgery, radiation therapy, and 
chemotherapy have been used in various combinations; however, the extent of 
resection and use of adjuvant chemotherapy or radiation therapy have not been clearly 
identified to be associated with a survival advantage (Jallo GI, 2003).  
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Before the advent of microsurgery and MRI, most surgeons and neurosurgeons were 
reluctant to attempt many spinal tumor surgeries due to the technical difficulties. 
Under these conditions, the neurological risk of resecting intramedullary neoplasms 
was considered unacceptably high, and this led to the development of a conservative 
treatment concept with biopsy, dural decompression and subsequent radiation therapy 
regardless of the histological diagnosis. Thus, the treatment strategy for 
intramedullary tumors gradually developed, and still continues to evolve, to an 
aggressive surgical concept. This biopsy or subtotal surgical resection only, involved 
field radiotherapy strategy for intramedullary tumor is administered even till 
nowadays in some developing areas. Since most intramedullary tumors are low-grade 
neoplasms, complete or even near-complete resection results in a good long-term 
progression-free survival with acceptable neurological morbidity (Constantini S et al, 
2000). The use of MRI has dramatically improved the anatomical understanding of 
the morphological pathology; and the use of intraoperative neurophysiological 
monitoring has tremendously increased the understanding of the functional integrity 
of the spinal cord pathways during surgery and the process of neurological recovery 
thereafter. Nevertheless, differences of opinion still exist about patients suffering from 
an intramedullary tumor and their optimal individualized treatment. In spite of the 
advances in surgical treatment, the old concept of ‘biopsy and radiation’ is apparently 
not extincted (O’Sullivan C, 1994; Houten JK, 2000). Today a total or near-total 
resection should be attempted with surgery for all spinal gliomas for an optimal 
prognosis and to confirm the histological diagnosis. (Karl FK, 2007). 
Despite this lack of consensus, surgery followed by radiation therapy, especially for 
incompletely resected lesions and recurrent tumors, is a common treatment paradigm. 
Several studies indicate that the use of postoperative radiation therapy modestly 
improves both local control and survival in spinal cord ependymomas and 
astrocytomas. Modern treatment planning and imaging allow more accurate target 
definition and respect for related normal tissue tolerances (Isaacson SR, 2000; 
Minehan KJ, 1995; Houten JK, 2000). But no study has convincingly demonstrated a 
beneficial effect of radiation therapy on survival or neurological function for 
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low-grade tumors so far.  
With new drugs widely used for chemotherapeutic management of central nervous 
system tumors, some have been tried for intramedullary tumors. Only the 
higher-grade glial tumors have been treated on a larger scale with a combination 
treatment which includes chemotherapy (Allen JC, 1998). Only recurrent low-grade 
tumors have been treated with chemotherapy. Temozolonide demonstrated a modest 
efficacy with acceptable toxicity in a group of 22 patients (Chamberlain MC, 2008). 
Besides that, there is only little experience regarding the effect of chemotherapy on 
spinal gliomas (Chamoun RB, 2006). Given the recent advances in the 
chemotherapeutic treatment of cranial malignant gliomas (Stupp R, 2005) and with 
the guide of tumor molecular prognostic factors, a standard chemotherapy regimen 
could possibly be started before the time of tumor progression or with tumor relapse 
of spinal gliomas in the foreseeable future (Taylor, MD, 2005; Richard AR, 2007). 
 
1.2 O
6
-Methylguanine DNA methyltransferase (MGMT)  
1.21MGMT protein molecular structure and function 
The MGMT gene on chromosome band 10q26 encodes a DNA repair protein that 
removes alkyl groups from the O6 position of guanine, an important site of DNA 
alkylation (Gerson SL, 2004). It contains five exons and four introns 
(length > 170 kb). The promoter region is CpG-rich, lacks TATA and CAAT boxes 
and has ten Sp1 transcription factor binding sites and two glucocorticoid response 
elements (GREs). MGMT protein, as a DNA repair protein, is a small enzyme-like 
substance of 207 amino acids (MW of 23 kDa). In several ways, MGMT protects the 
cellular genome from the mutagenic effects of alkylating agents (Kaina C, 2007).  
MGMT can contribute to alkylating agent resistance (Middlemas DS, 2000). It exerts 
its protective effect by removing cytotoxic chloroethyl and methyl adducts from the 
O6 position of guanine toan internal cysteine, yielding guanine and S-alkylcysteine 
(Pegg AE, 1995). The MGMT-mediated repair process is unique and differs from 
other DNA repair pathways because MGMT is not part of a repair complex but acts 
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alone. This repair mechanism mediated by MGMT involves the transfer of the alkyl 
group from the alkylation site of the DNA to an internal active site represented by a 
cysteine (Cys) residue in the amino acidic sequence of the MGMT protein. Because 
the alkyl receptor site is not regenerated, the number of O6-alkylguanine adducts that 
can be removed from DNA in vivo is limited by the number of MGMT molecules and 
the rate of synthesis of the protein. There is evidence that MGMT limits the 
cytotoxicity of cyclophosphamide (Friedman HS, 1999). MGMT is ubiquitously 
expressed in normal human tissues, although at variable extent in selected tissues and 
on individual bases (Gerson T, 1986), but is overexpressed in all types of human 
tumors, including colon cancer, glioma, lung cancer, breast cancer, leukemia, 
lymphomas, and myeloma. MGMT activity of normal and neoplastic human brain 
specimens has been reported (Citron M, 1991). The values for normal brain and 
primary brain tumors are similar and vary up to 40-fold for normal tissue and 100-fold 
for tumors (Citron M, 1991). To date, there has been no paired comparison of the 
MGMT content of normal and neoplastic brain from the same patient. The level of 
MGMT expression is protean in various tumor tissues because of epigenetic 
inactivation of the MGMT gene. In particular, hypermethylated CpG islands in the 
MGMT promoter seem to be the most important mechanism for MGMT gene 
silencing and for the down-regulation of the expression. Several studies have reported 
transcriptional silencing of this gene in up to 50% (Shen K, 2005). MGMT silencing 
is also often observed in tumors in which a number of other genes are suppressed by 
methylation. 
 
 
1.22 MGMT and chemosensitivity 
MGMT is implicated in the removal of DNA alkyl adducts from the O6 position of 
guanine, one of the targets of alkylating drugs. Methylation of the MGMT promoter 
results in gene inactivation, thus potentially leading to increased sensitivity to 
treatment with alkylating agents. It has been observed that MGMT gene expression 
seems to be related to the methylation of the MGMT promoter, MGMT enzyme 
  16 
activity, protein expression and cell resistance to anti-tumor alkylating agents by a 
series of experiments, which could predict a possible chemosensitivity. Therefore the 
MGMT methylation status is of therapeutic and prognostic interest (Kaina B, 2007).  
Failure of nitrosoureas against CNS tumors results from tumor cell resistance to DNA 
damage impacted by these drugs (Demetrius M, 1999). It has been found that those 
tumors with high MGMT activity and abundance of MGMT protein were resistant to 
alkylating chemotherapeutics, while those with low MGMT activity and little MGMT 
protein expression were sensitive. Hence, MGMT behaves as a predictor of response 
to chemotherapy and also may be a prognostic biomarker. Given MGMT is one of the 
most important factors determining drug resistance to alkylating therapy, strategies 
have been developed to inhibit MGMT expression in tumors with the aid of MGMT 
inhibitors, and further enhance the anti-neoplastic efficiency of alkylating agents. 
 
1.23 MGMT and primary central nervous system tumor 
Because brain gliomas are the most common primary central nervous system tumor, 
most studies assess the MGMT status in brain tumors focused on serial patients with 
glioma. The level of MGMT protein in cranial malignant glioma varies widely 
ranging from almost undetectable to very high level. Esteller et al investigated the 
relationship between MGMT promoter methylation and response to carmustine in 47 
patients with gliomas. In this study, MGMT gene promoter methylation was 
associated with a better response to chemotherapy, greater overall survival and longer 
time to progression (Esteller, 2000). Several studies reported similar results recently 
(Nakasu, 2007; Brandes, 2008). The low MGMT protein expression was further 
identified as an independent favorable prognostic factor in terms of OS of brain 
glioma (Nagane, 2007). These results were consistent with the findings in the large 
phase III EORTC/NCIC trial conducted for patients with newly diagnosed GBM 
(Hegi, 2005).  
Although there are many research efforts on MGMT with brain glioma, similar 
studies for the spinal glioma are rare. Richard et al have reported one case of a 
28-year-old woman with a recurrent high-grade spinal cord astrocytoma (Richard AR, 
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2007), where the genetic testing revealed that this tumor did not express MGMT, so 
they treated the patient with temozolomide (TMZ), which led to functional recovery 
and regression of the residual tumor. This is the first and only case reported in the 
literature correlating MGMT expression with the clinical response of a spinal glioma 
treated with alkylating chemotherapy. The systemic status of MGMT in spinal glioma 
and its correlation to clinical outcome is still unknown. 
 
1.3 Ku80 introduction 
1.31 Ku80 protein molecular structure and function 
Ku is a heterodimeric protein of 70 and 80 kDa polypeptides that also is abundant in 
nuclei of cultured human cells. Ku binds DNA ends and targets DNA-PKcs to DNA 
strand breaks (Moll U, 1999). The kinase is presumed to activate or regulate the 
components that repair Double-strand breaks (DSBs). Ku80 is derived from the 
XRCC5 gene localized to chromosome 2q33`q35 in human cells. Ku80 binds to DNA 
ends, nicks, gaps, and hairpins. In vitro, Ku forms a complex called DNA-dependent 
protein kinase (DNA-PK) by associating with a 450-kDa catalytic subunit and 
DNA-PKcs. So, DNA-PKcs and Ku80 expression was usually parallel. The highest 
levels were observed in spermatogenic cells, and in neurons and glial cells of the 
central and autonomic nervous system. Ku80, Ku70, DNA-PKcs, Xrcc4, and DNA 
ligase IV are critical for the repair of DNA ends by nonhomologous end joining 
(NHEJ). The Ku plays a key role in multiple nuclear processes, e.g., DNA repair, 
chromosome maintenance, transcription regulation and VJ recombination (Skorokhod 
OM, 2006). Although both Ku proteins and DNA-PKcs bind independently to the 
DNA ends, the greater part of this function is performed by the Ku70/Ku80 
heterodimer, rather than DNA-PKcs itself (Hammarsten O, 1998). 
Ionizing radiation directly produces DSBs, and it is believed that a single unrepaired 
DSBs will result in a broken chromosome and be responsible for cell death. Mice 
deleted for Ku70 or Ku80 exhibit hypersensitivity to γ-radiation, defective V(D)J 
recombination, genomic instability and early aging with low-cancer levels (Holcomb 
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VB, 2006). The similar phenotype suggests Ku70 and Ku80 function is restricted to 
the Ku heterodimer. However, there is reason to believe Ku70 or Ku80 may function 
independent of the Ku heterodimer. Each subunit enters the nucleus through a 
different nuclear localization signal (Lim JW, 2008) and Ku70 levels increase in 
response to -radiation without Ku80 (Brown KD, 2000). Li suggested p53-mutant 
fibroblasts are more sensitive to streptonigrin and paraquat when deleted for Ku80 as 
compared with Ku70. Thus, Ku80 may function outside the Ku heterodimer to 
influence DNA damage repair (Li H, 2009). 
 
1.32 Ku80 and radiosensitivity 
The integrity of a cell's DNA is of paramount importance for survival; therefore, all 
living cells have evolved mechanisms for repairing DNA lesions. DSBs are among 
the most critical lesions in chromosomal DNA are easy induced by ionizing radiation 
(Moll U, 1999). Cells mutated by the deletion of any of the previously mentioned 
genes are hypersensitive to ionizing radiation and defective in repairing DNA DSBs. 
The capability for DNA DSBs repair is crucial for inherent radiosensitivity of tumor 
and normal cells. The success of DSBs repair in tumor cells is the major cause for 
radiotherapy failure, leading to prolonged tumor cell survival. Thus, molecules that 
are involved in DSBs repair may be potential prognostic markers for the prediction of 
radiotherapy outcome, and hence, for optimization of treatment.  
Although there are exceptions, it is supported by results from several clinical studies 
that Ku protein expression is correlated with radiation treatment outcome (Friesland 
KL, 2003; Harima S, 2003). Upregulation of the Ku80 protein following ionizing 
radiation exposure has been reported previously (Otomo H, 2004). Conversely, 
tumors with a low percentage of Ku80-positive cells tend to be radiosensitive. 
 
1.33 Ku80 in CNS and glioma  
Ku80, DNA-PKcs and Ku70 mRNAs were expressed in all normal tissues with 
relatively little variation in their levels. Many, but not all, cortical neurons in the gray 
matter and in the subcortical white matter stain strongly positive for DNA-PKcs and 
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Ku80. A significant subset of glial cells in the grey and white matter also stain 
strongly positive for DNA-PKcs and Ku80. Microglias were always negative for 
DNA-PKcs and Ku80. Parasympathetic ganglia, as well as myelin-producing 
Schwann cells of the autonomic nervous system have also been tested strongly 
positive for DNA-PKcs and Ku80 (Moll U, 1999). 
Although most cancerous tissues were consistently positive for Ku80 (Moll U, 1999), 
radiotherapy is an important component of multimodal treatment for many malignant 
brain and spinal gliomas in clinic. But the research efforts on Ku80 with CNS glioma 
are rare. There are few studies performed with established cell lines about Ku80 
expression in gliomas (Takashi O, 2004; Dhandapani KM, 2007; He F, 2007; 
Holcomb VB, 2006). Takashi O described 2 human glioblastoma cell lines, U87MG 
and A172 presenting a greater percentage of radioresistancy. The expression of DNA 
repair gene Ku80 in these cell lines could be found in a large percentage (Takashi O, 
2004). Dhandapani KM studied glioma cell lines with the Ku80 inhibitor Curcumin, 
and investigated a potential therapeutic role in glioma. The results suggested that the 
expression of Ku80 might contribute to generally poor prognoses in human (T98G, 
U87MG, and T67) and rat (C6) glioma cell lines (Dhandapani KM, 2007). Besides 
Except studies performed with established glioblastoma cell lines, no other one is 
known about Ku80 expression in brain glioma, and so far, the expression and 
significance of Ku80 in spinal glioma has not been analyzed. 
 
1.4 Ki67 introduction 
1.41 Ki67 protein molecular structure and function   
Ki67 is a large nuclear protein antigen and correlate with cell-cycle and proliferation. 
Its molecular weight is 345kd and 395kd. The Ki67 gene is located on chromosome 
10q. The expression of Ki67 is mainly in the mid to late G1 phase, S phase and G2 
phase of the cell-cycle, then the expression increases gradually and reaches the top in 
mitotic phase. It is an important structure for the maintenance of mitosis and it plays 
an important role in keeping the structure of DNA stable, it is a sensitive indicator of 
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cell proliferation (Sallinen P, 1994; Onda K, 1994). 
The proliferation activity of tumours can be assessed by means of Ki-67 
immunohistochemistry, which is now widely used in clinical pathology and 
neuropathological diagnostics. Burger and co-workers were the first to show the 
strong association between Ki-67 immunopositivity and glioma grade in freshly 
frozen samples of brain astrocytomas (Burger PC, 1986). Based on a large number of 
studies, the added prognostic information provided by Ki-67 immunostaining is now 
well established with regard to malignant tumors. 
 
1.42 Ki67 and the proliferation 
The latest WHO classification of central nervous system tumors (Louis DN, 2007) 
includes Ki-67 as an additional tool in histological typing and grading, although it 
cannot be regarded as being entirely prognostic in individual cases. 
Haapasalo showed with immunostaining that Ki67 is useful as an adjunct of 
morphological diagnosis and grading of astrocytic tumors. Ki67 prognostic value is 
best expressed for optimal sensitivity and specificity with limit values of 7.5%, 10%, 
and 12.5 %, respectively. Using these limits a highly significant distinction was found 
in survival analysis (Haapasalo J, 2005). 
More recently Ki67 have been widely used as markers to predict outcome in various 
malignancies. Ki67 is an established marker for proliferative index in cycling cells. Its 
presence in large proportion of cells suggests an aggressive neoplasm (Tsutsumi Y, 
1995; Kammerer U, 2001; Sallinen P, 2000). 
 
1.43 Ki67 in glioma  
In a retrospective study on 70 ependymomas study treated between 1994 and 2001 
Vaishali found that the expression of p53 and Ki 67 was correlated with the grade of 
tumor. The mean Ki -67 and p53 indices were significantly higher in grade III tumors 
as compared to grade I and II tumors. The difference in expression of Ki67 and p53 
was highly significant between grade II and grade III tumors (P value < 0.0001). Four 
out of 11 cases of clear cell ependymomas showed higher Ki 67 indices as compared 
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to classical grade II ependymomas (Vaishali SS, 2004). Other studies looked at the 
expression of Ki67 in various grades of brain ependymomas and recurrent tumors. 
These authors confirmed that the Ki67 labelling index is a very important prognostic 
marker for brain ependymomas (Rushing EJ, 1981; Suzuki S, 2001; Verstegen MJ, 
2002). Haapasalo et al studied Ki67 in different grades of astrocytic tumors and found 
that Ki67 revealed proliferating astrocytoma nuclei, which were scarce in low grade 
tumours and abundant in glioblastoma (Haapasalo A, 2005). 
Despite many studies performed with established brain glioma showing the 
expression and significance of Ki67 in CNS tumor, there is, to our knowledge, no 
literature about Ki67 expression in spinal glioma so far. Maybe it is also due to the 
spinal glioma infrequence.  
 
1.5 Questions and aims of the study 
As mentioned above, spinal glioma, as one of the more uncommon CNS tumor, has 
not been given enough attention due its rare incidence. Until nowadays, there is no 
consensus regarding the management of spinal cord glioma. Surgery, radiation 
therapy, and chemotherapy have been used in various combinations; the treatment 
modalilities of what extent of resection and how or when using of adjuvant 
chemotherapy or radiation therapy are not clearly associated with a survival 
advantage. The prognostic significance of some clinical factors as patient's age, tumor 
location, volume of resection, protocols of adjuvant therapy have been stated but other 
studies have yielded conflicting results. More precise molecular prognostic factors are 
important not only for division of patients with spinal glioma into specific risk groups 
for identification and assessment of appropriate therapies and to predict the survival, 
but also for comparing results of clinical trials. It is clear that the biological 
mechanisms involved in pathogenesis of spinal glioma are complex but deserve 
further study. Obviously, a better insight of its biology is crucial to choose the best 
treatment regimen and improve the prognosis. If it were possible to interfere with the 
chemosensitivity and radiosensitivity and reasonably block spinal tumors prone for  
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recurrence, an alternative therapeutic approach might be found. 
Given that MGMT is one of the most important factors determining drug resistance, 
Ku80 determining radiosensitivity, Ki67 determining prone of relapse, the expression 
of MGMT, Ku80 and Ki67 in spinal glioma remains unclear. Herein, we postulate that 
the expression of the MGMT, Ku80 and Ki67 in spinal glioma is of interest for the 
therapy and its recurrence. It is for this reason that our study was designed to detect 
the expression of MGMT, Ku80 and Ki67 on spinal glioma by IHC staining to 
address the following questions: 1) to determine the expression level of Ku80 and 
MGMT for correlation with the clinical status of the patients. 2) Evaluate the 
relationship between MGMT and Ki67, Ku80 and Ki67 expression level and clinical 
outcomes. 3) Appraise the relationship between Ku80 expression level and 
radiotherapy, MGMT expression level and chemotherapy effects, Ki67 expression 
level and chemotherapy effects. 4) Judge the expression level of Ki67 for correlation 
with the histological grade or subgroups of patients. 5) Estimate the relationship 
between Ki67 expression level and recurrence of the tumor. Thus determine, if these 
immunophenotypes are prognostic factors in spinal glioma. They may be new markers 
for anticipating curative effects. There also might be a strategy for an optimal 
individualized treatment according their molecular prognostic factors.
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2. Materials and methods 
2.1 Patients and tissue samples 
2.11 Patients and eligibility 
We have collected spinal gliomas tissues and clinical data from 65 patients. Among 
them 39 patients were diagnosed and treated at the Department of Neurosurgery, 
University Medical Center of Schleswig-Holstein, Campus Kiel, Germany; 26 
patients were diagnosed and treated in China, their tissues were kindly provided by 
Prof. Sien Zeng (Department of Pathology, affiliated hospital of Guilin Medical 
College, China), Xinwei Li (Department of Neurosurgery, 3th Hospital affiliated 
School of Medicine, Zhejiang University, China) and Yi Luo (Department of 
Neurosurgery, Liu Zhou hospital of Chinese Traditional Medicine, China).  
Patients selected and excluded criterions for this study: (1) Histological characteristics 
of these cases fulfilled the criteria of the latest World Health Organization (WHO) 
classification of tumors of the nervous system (Louis DN, 2007). (2) Patients were 
required to have a life expectancy greater than 1 month, with possible detailed clinical 
data at diagnosis and therapy and during follow up. (3) Availability of adequate tissue 
specimens for histologic typing and immunohistochemistry. (4) Adequate hematologic, 
renal and hepatic function. (5) Patients who had a history of cerebral glioma then 
transfer to spinal were excluded from the study. (6) Patients previously treated by 
MGMT inhibitor (for example: O6-Benzyl-2’-deoxyguanosine (dBG)) or by 
chemotherapy with alkylating within 3 months prior to diagnosis were excluded. (7) 
Patients previously treated by Ki67 and Ku80 inhibitor (for example: 
Gamma-linolenic acid (GLA)) within 3 months or received radiotherapy within 1 year 
of diagnosis were excluded. Patients who died from postoperative complications were 
not included in the study.  
 
2.12 Clinical data of patients 
Patients treated from April 1992 to August 2009 were included in the study. 
Fifty-nine tumor tissues were newly diagnosed, and 6 were recurrent after prior 
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operation. All tissues were reviewed by neuropathologists affiliated with the 
Department of Neurosurgery, University Medical Center of Schleswig-Holstein, 
Campus Kiel, Germany. Tissues from China had additional H.E staining（stain 
nucleus with Hematoxylin and stain cytoplasm with Eosin ）and dehydrate and were 
classified by a neuropathologist of the Department of Neurosurgery, UK S-H Campus 
Kiel according to the WHO histopathologic criteria. Clinical follow-up was obtained 
until October 27, 2009, or until death or loss of follow-up. 56 patients had undergone 
tumor total removed and 9 patients had undergone subtotal tumor resection. 18 
patients have received alkylating chemotherapy, 16 patients received radiotherapy and 
7 patients received chemotherapy in combination with radiotherapy. Except for the 
operation, the treatment of patients varied. There were no standard criteria for 
adjuvant treatment. This was mainly done depending on individual histological 
diagnosis, if the tumor was relapsing, the stage of the disease, the health condition and 
the individual hospital. All patients were followed up postoperatively by clinical 
examination and MRI scanning at least at 12 month intervals or when recurrence was 
suspected. Those patients with a complete remission or the stable disease were 
followed up by phone calls and were not always reexamined if being in good health. 
 
2.13 Histological diagnosis and classification  
Tumour diagnosis and grading were definitively established according to the WHO 
histopathologic criteria (Louis DN, 2007) and were systematically reviewed by an 
expert neuropathologist. These glial tumors encompass: (i) grade I (including 
Ependymoma I, Ganglioglioma I and Pilocytic astrocytoma I), (ii) grade II (including 
Ependymoma II, Ganglioglioma II and Astrocytoma II ) ,(iii) grade III (including 
Ependymoma III and Astrocytoma III ) and (iiii) grade IV (Glioblastoma IV). 
Distribution of the patients according to the WHO classification is presented in 
Table1. The spinal gliomas were located as follows: In 5 patients the tumors were 
located mainly in medulla oblongata, in 18 patients the tumors were located mainly in 
cervical myelon, in 22 patients the tumors were located mainly in thoracic myelon and 
in 20 patients located mainly in the lumbar myelon. 
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Tab 1. Demographic and pathological characteristics (N=65) 
Histologic subtypes and grades Patients number N=65  Patients (%) 
Grade I 13  20.0 
Grade II 35  53.5 
Grade III 5  7.7 
Grade IV 12  18.5 
Grades I to IV: according to the World Health Organization 
2.2 Immunohistochemistry (IHC) 
2.21 Experimental instruments 
Pressure cooker：Sicomatic-L, Germany 
Electronic precision scale：A200S-*DI，SARTORIUS GMBH GOETTINGEN, 
Germany  
Micropipettes and tips：EPPENDORF，Germany  
Optical microscopy：OLYMPUS，BH-2，Japanese 
2.22 Experimental reagents 
（1）TBS （Tris-GerufferK Kodsalzlsg pH7.8） 
Tri-sodium base    (Sigma T 1503)           0.9 g 
Tris-HCL        (Sigma T 3253)           6.85g 
NaCL           (Merck 1.06404)          8.78g 
Distilled water                          1000 ml 
(2) EDTA-Puffer (TEC-Puffer pH7.8) 
Tri-sodium base     (Sigma T 1503)            2.5 g 
EDTA             (Merck 1.08418)           5.0 g 
Tri-Sodium Citrate   (Merck 1.06448)           3.2g 
Distilled water                               1000 ml 
（3）AEC Reagent：Sigma.  
（4）Ku80,Ki67 Mouse Monoclonal Antibody: 1:200 LAB VISION CORP ORAT 
ION.  
（5）MGMT Mouse Monoclonal Antibody: 1:60 THERMO SCIENTIFIC. 
（6）Second antibody: Anti-Mouse and Rabbit Histofine: MEDAC, Germany. 
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（7）Tris                     Merck Germany. 
（8）HCL                    Merck Germany. 
（9）NaCL                   Merck Germany. 
（10）Skimmed milk powder 5%  Roth Germany. 
（11）Hematoxylin Solution      Merck Germany. 
（12）3% hydrogen peroxide     Merck Germany. 
2.23 Control samples 
According to antibody data sheets, colon cancer tissue served as normal control 
samples for MGMT, normal tonsil tissues for Ku80, and Ki67. For positive and 
negative (omission of first antibody) control of the staining reaction, these sections 
were stained parallel to all cases in our study cohort. Each antigen has a preferred 
method of antigen retrieval, and each antibody was optimal diluted. Positive control 
experiments were performed to find optimal staining conditions before 
immunohistochemical stains could be proceeded.  
First, we stained without antigen retrieval, and also used the heat-induced epitope 
retrieval with a pressure cooker. Antigen retrieval was tested in Tris/EDTA pH 6.0, 7.8 
and 9.0 buffers. The antigen retrieval time was controlled 3-4 minutes for MGMT, 
Ku80 and Ki67 as soon as the cooker had reached full pressure. Antibody 
concentrations were diluted to 1:20, 1:40, 1:60, 1:80 for MGMT, to 1:100, 1:200 for 
Ku80, and 1:100, 1:200 for Ki67 as recommend on the data sheets. Finally a dilution 
of 1:60 was determined as the optimal dilution for MGMT, 1:200 for Ku80 and 1: 200 
for Ki67. 
2.24 Experimental process  
The immunohistochemistry protocol was as follows. 
2.241. Fixing and embedding the tissue 
The spinal glioma tissue was formalin-fixed and paraffin-embedded. 
2.242. Cutting and mounting the section  
After fixation and paraffin-embeding, the probes are cut in a microtome to the desired 
thickness of 3 microns and mounted onto the slide. 
2.243 Deparaffinizing and rehydrating the sections 
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The sections were dewaxed in xylene and rehydrated by passage through a graded 
ethanol series to distilled water. The step in details is performing the following washes 
in proper order with sections placed in a rack. 
1). Xylene:       2 x 5 minutes 
2). Xylene 1:1 with 100% ethanol:  2 x 5 minutes 
3). 100% ethanol:     2 x 2 minutes 
4). 96% ethanol:      2 x 2 minutes 
5). 70 % ethanol:      2 minutes 
6). Distilled water to rinse 
2.244 Antigen retrieval 
The appropriate antigen retrieval buffer is added into the pressure cooker and the 
slides transferred from the distilled water to the pressure cooker. When the cooker has 
reached full pressure, the slides remain there up to 3 minutes for Ku80 and Ki67 
antigen retrieval and 10minutes for MGMT. Once de-pressurized, the slides are rinsed 
immediately with distilled water. 
2.245 Immunohistochemical staining process 
1). Slides are kept in distilled water for 1 minute. 
2). Slides are kept in 70% ethanol for 1 minute. 
3). 96% ethanol for 1 minute. 
4). Endogenous peroxidases were blocked with 3% hydrogen peroxide in 
Tris-buffered saline (TBS) for 10 minutes. 
5). 96% ethanol for 1 minute. 
6). 70% ethanol for 1 minute. 
7). Distilled water for 1 minute. 
8). Blocking of nonspecific binding was accomplished in 5% skimmed milk for 10 
minutes. (This step is only used for MGMT). 
9). Slides were washed in distilled water for 1 minute. (This step is only used for 
MGMT). 
10). Sections were washed 3 times in TBS for 2 minutes. 
11). Slides were drained for a few seconds. 
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12). Primary antibody was diluted (1:60 for MGMT,1:200 for Ku80 and 1:200 for 
Ki67) according to the manufacture protocol. 100 µL of primary antibody fine-tuned 
was added.  
13). Anti-MGMT mouse monoclonal antibody remained in room temperature 
overnight (18 hours), anti-Ku80 in room temperature for 30 minutes, and anti-Ki67 at 
37°C for 40 minutes. 
14). Slides were washed in distilled water for 2 minutes after incubation. 
15). Sections were washed 3 times in TBS for 2 minutes. 
16). Sections were incubated at room temperature for 30 minutes with 100 µL of 
anti-mouse and rabbit histofine (Secondary antibody). 
17). Sections were washed 3 times in distilled water for 5 minutes. 
18). Slides were than washed 2 minutes in TBS 3 times. 
19). Slides were incubated for 20 minutes at room temperature with 100 µL AEC 
complex (2ml AEC +1µL 30% hydrogen peroxide), and then washed in distilled water 
for 1 minute 
20). Sections were counterstained with hematoxylin for 5 minutes. 
21). Slides were washed in running tap water for 5 minutes and then washed in 
distilled water for several seconds, mounted using one drop of aqua tex (Merck, 
Germany). 
2.25 Viewing the staining under the microscope and results evaluation 
Two independent experienced scientists (one a experienced neuropathologist) without 
prior knowledge of the patients’ clinical outcomes investigated all histologic 
specimens. Each tumor was evaluated for these gene proteins and given a score for 
the percentage of immunoreactive positive cells density of all tumor cells. One 
thousand neoplastic cells per specimen were evaluated at x400 magnification and the 
ratio (%) of MGMT, Ku80, and Ki67 immunoreactive neoplastic cells were recorded. 
The final result is the sum of the percentage score. On the basis of the percentages of 
positive cells in the tumors, these tumors were defined as low MGMT expression, low 
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Ku80 expression when there are no or fewer than 50% positive cells, and high 
expression when positive rate was more than 50%.For Ki67, low expression when 
there are no or fewer than 10% positive cells, and high expression when positive rate 
was more than 10%. 
2.3 Statistical analysis 
Tumor complete resection was defined as the disappearance of all contrast 
enhancements in MRI or according the operation record. Tumor partial resection was 
defined as the tumor residual at contrast enhancements in MRI or according to the 
operation record. Tumor relapse also was defined as the enhance MRI in tumor size 
compared with the baseline or according patient’s history. End points of the study 
were overall survival (OS) and progression-free survival (PFS). PFS was evaluated 
from the first day of treatment to relapse, progression or death, or to the last date of 
follow-up, and OS was calculated from the first day of treatment of the tumor to death 
for any reason or to the last date of follow-up. Patients who did not experience the 
event of interest with respect to OS or PFS were considered as censored observations 
with time from first diagnosis to last follow-up visit as the censoring time.  
A descriptive study of all the variables included in the study was carried out. The 
absolute expression level of MGMT, Ku80 and Ki67 in all groups classified according 
to variables was analyzed by One-way ANOVA method. The quantitative variables 
were expressed in terms of their centralisation and dispersion measurements, and in 
some cases were categorized in accordance with their median value. Chi-square test 
was applied to estimate the relation between the expression of MGMT, and Ki67, 
Ku80 and Ki67, recurrence and patient characteristics, metastasis and patient 
characteristics. Correlation analysis was performed between the death/survival, 
chemotherapy, radiotherapy, recurrence, group, subgroup and the expression of 
MGMT, Ku80, Ki67. Kaplan–Meier methodology was applied in order to determine 
the effect of the different variables on survival and on PFS. Parameters possibly 
correlated with disease progression and survival were age, gender, tumor localization, 
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surgical type, and use of alkylating agents, radiotherapy, expressions of MGMT, Ku80 
and Ki67 protein. These variables were estimated with their mean and 95% 
confidence interval. The end-point variable of interest was OS and PFS. The log-rank 
test was applied in order to verify the probabilities of accumulated survival and PFS 
in accordance with different strata of variables. A p<0.05 value was considered to be 
of statistical significance. Analyses were performed with the use of SPSS 17.0. 
3. Results 
3.1 Patient characteristics and treatment  
There are 65 patients with spinal glioma in this study. All data of these patients are 
lined in Table 2a and Table 2b.  
Tab 2a.  Primary clinical data of the patient characteristics 
No Se Ag Co Diagn 
(grad) 
Re Met Tu:Site Op. 
Type 
CT 
(Al) 
RT MGMT 
(%) 
Ku80 
(%) 
Ki67 
(%) 
KPS PFS 
(Mon) 
OS 
(Mon) 
S/D 
1 M 64 G GBMIV no no MO- C2 TR yes yes 41.6 69.2 20 80 13 13 S 
2 F 42 G E II no no L2 TR no no 88.2 66 7 80 135 135 S 
3 M 42 G E II no unk C4-T4 SR yes no 3 55.8 7 unk unk unk unk 
4 F 58 G E II yes no C4-T2 TR no yes 18.4 77.2 2 50 1)10, 2)131 141 S 
5 F 16 G E II yes no C2-5 TR unk unk 4.2 84 5 unk 1)9, 2)29 38 unk 
6 M 38 G E II yes no L2 TR no yes 90.6 72 5 100 1)23, 2)31 54 S 
7 M 9 G E II no no L1-3 TR no yes 6.4 74 10 90 54 54 S 
8 F 42 G E II no no L1-2 TR no no 95.2 51 2 90 51 51 S 
9 F 21 G E I yes no L2-3 TR unk unk 89 21 2 90 1)48,2)12,3)36 96 unk 
10 F 38 G E II no no C3-5 TR no no 86.4 68.8 2 80 42 42 S 
11 M 35 G E II no no C6 TR no no 94 71 1 70 9 9 S 
12 F 46 G E II no no L2 TR no no 81 89.2 1 60 24 24 S 
13 F 33 G E II no no T8-12 TR unk unk 94.4 78 1 70 9 9 unk 
14 F 50 G E II no no L2 TR no no 18.2 2 2 80 10 10 S 
15 F 48 G E II no no L1 TR no no 79 74 5 unk 3 3 unk 
16 F 53 G E I no no C7-T1 TR no no 78.2 83.2 1 70 78 78 S 
17 M 47 G E I no no L2 TR no no 16 82.8 1 90 73 73 S 
18 F 62 G E I no no T4-L1 TR no no 51 68 2 100 72 72 S 
19 M 49 G E I no no L1-2 TR no no 16 73 1 80 65 65 S 
20 F 22 G E I yes no T12-L4 TR unk unk  24.4 81 1 unk 1)2,2)48,3)96 146 unk 
21 M 22 G E II unk no L3 TR no no 51.2 73.6 5 unk 40 40 unk 
22 F 30 G E II yes unk C4-6 TR unk unk 3 76 1 unk 1)47,2)9,3)20 76 unk 
23 F 43 G E I no no L1 TR no no 98.6 48 1 unk 22 22 unk 
24 F 57 G E II no no C6-7 TR no no 9 85.5 1 50 107 107 S 
25 F 44 G E I no no T12-L12 TR no yes 94.2 89.2 1 100 100 100 S 
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26 M 57 G E I no no L1-2 TR no yes 2 67.6 1 70 92 92 S 
27 F 27 G E II no no T6-9 TR no no 3 62.8 2 80 175 175 S 
28 F 64 G E II no no C5-7 TR no no 28.4 32 0 90 175 175 S 
29 F 53 G E II unk unk T12-L1 TR no no 35 84 3 0 174 174 D 
30 F 36 G E II no no T12-L2 TR unk unk 90.6 30 1 unk 88 88 unk 
31 F 34 G E II yes no L1-2 1)SR,2)TR unk unk 32.8 22.4 2 unk unk unk unk 
unk 32 M 37 G E II no no T3-5 TR unk unk 22.2 34.8 1 unk 35 35 
33 
34 
M 
M 
61 
61 
G 
G 
E II 
E II 
no 
no 
unk 
no 
T12-L1 
C5-6 
TR 
TR 
no 
unk 
no 
unk 
7 
8.8 
66 
41.6 
2 
1 
50 
unk 
162 
10 
162 
10 
S 
unk 
35 F 62 G E II no no L1-2 SR yes no 90.4 93.2 1 60 10 10 
26 
S 
36 F 69 G A II yes no T2 SR no no 38 38 1 80 1)4, 2)22 S 
37 M 11 G Gli II no no C1-2 SR yes yes 75.2 40 5 60 31 31 S 
38 F 30 G GBMIV yes no T7 TR unk unk 89.2 44 80 unk 1 1 unk 
39 F 41 G A III no no MO- C1 TR yes yes 8 74 20 90 1 1 S 
40 
41 
42 
43 
F 46 C E II no no C4-T1 TR yes no 76 42.4 1 50 102 102 S 
F 
M 
F 
43 
34 
21 
C 
C 
C 
E III 
E I 
A III 
yes 
no 
yes 
no 
no 
yes 
T1-T6 
T2-T7 
L1-2 
TR 
TR 
TR 
yes 
yes 
no 
yes 
no 
no 
16 
30 
58 
0 
48 
37.2 
10 
1 
15.2 
70 
100 
0 
41 
62 
1)14, 2)26 
41 
62 
40 
S 
S 
D 
44 F 36 C E II no no T11-T12 TR yes yes 52 84.4 0 60 94 94 S 
45 F 27 C E II no no C5-T1 TR yes no 80 91.6 10 80 13 13 S 
46 M 56 C E II no no C5-C7 TR unk unk 68 94.8 1 90 6 6 S 
47 F 25 C E II no no MO-C4 TR yes no 24 86 2 50 17 17 S 
48 M 5 C  A I no no T7-L1 TR no no 33.2 84 6.4 50 15 15 S 
49 M 45 C E I no no L1 TR no no 52 22 0 80 40 40 S 
50  F 12 C GBMIV yes no C3-C7 TR no no 82 58 20.8 0 1)8, 2)5 13 D 
51 M  40 C GBMIV yes no T1-T3 TR yes yes 0 94 17.2 0 1)45, 2)3 48 D 
52  F 16 C GBMIV yes yes T11-T12 TR no no 0 70.4 6.8 0 4 5 D 
53 F  27 C E III  no no L1-L2 TR yes yes 72 72.2 9.8 100 22 22 S 
54 F  54 C E I  no no T12-L1 TR no no 12 97 12.2 70 27 27 S 
55 F  42 C E II no no C4-6 TR no no 16 0 11 90 45 45 S 
56 M  24 C GBMIV  yes no C4-7 SR no no 62 0 2.4 0 7 20 D 
57  F 52 C GBMIV   yes yes C2-3 TR yes no 0 0 29 0 33 36 D 
58  F 18 C GBMIV  yes yes C3-C6 TR no no 0 0 29.2 0 8 14 D 
59 M  35 C GBMIV   yes unk T10-L2 SR yes yes 0 0 11.2 0 27 38 D 
60 F  32 C E I  no no T5-6 TR unk unk 68 6.4 1.6 unk 40 40 unk 
61 F  38 C MBMIV  yes yes MO-C4 SR yes yes 42 82.4 19.6 0 11 21 D 
62  F 35 C  E II yes no C4-8 TR no no 26.6 94.6 1 70 14 14 S 
63  M 41 C A III  no no T1-3 TR yes yes 36 73 22 100 95 95 S 
64 M  43 C GBMIV  yes no T5-L1 TR 1)y,2)n 1)y,2)n 66 74 8.2 0 1)108, 2)16 124 D 
65  F 37 C GBMIV yes unk MO-C2 SR no no 63 80.4 9 0 4 8 D 
Abbreviations: Se, Sex; Ag, Age; Co, country; Diagn, diagnosis; Re, relapse; Met, metastasis; Tu, 
tumor;Op, operation; TR,Total resection;SR,Subtotal resection; OS, overall survival; PFS, 
progress free survival; M, male; F, female; S, survival; D, death; G, Germany; C, China; CT, 
  32 
chemotherapy;Al,Alkylating; RT, radiotherapy; RC, radiochemotherapy; NT, no treatment; MO, 
medulla oblongata; C, cervical myelon; T, thoracal myelon; L, lumbar spine; Grad, grade; E, 
ependymoma; A, astrocytoma; GBM, glioblastoma; Gli,Glioma; Mon, month; Unk, unknown；
Special note:for example 1)48,2)12,3)36 in PFS：2)12 mean the number of operation is the 
second operation and the month of progress free survival of this operation is 12 month. 
Tab 2b. The constitue of patients from Germany and China 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Country Tumor types Number(%) 
Germany E I 9（23.1%） 
 E II 25（64.1%） 
 E III 0 
 A I   0 
 A II 1（2.6%） 
 A III 1（2.6%） 
 G II  1（2.6%） 
 GBMIV 2（5.1%） 
Total  39(100%) 
China E I 4（15.4%） 
 E II   7（26.9%） 
 E III 2（7.7%） 
 A I  1（3.9%） 
 A II  0 
 A III 2（7.7%） 
 G II 0 
 GBMIV   10（38.5% 
Total  26(100%) 
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There are 65 patients in our study,39 patients recruited in Germany and 26 come from 
China. The group comprised 22 men and 43 women with a male/female ratio of 0.51; 
age ranged from 5 to 69 years (mean 39 years). The spinal gliomas were located as 
follows: In 5 patients the tumors were located mainly in medulla oblongata, in 18 
patients the tumors were located mainly in cervical myelon, in 22 patients tumors 
were located mainly in thoracic myelon and 20 tumors were located mainly in 
lumbar/lumbosacral myelon. 
 
All patients were diagnosed as spinal gliomas by a neuropathologist according to the 
World Health Organization (WHO) criteria. 9 patients had undergone subtotal 
resection at the time of initial diagnosis and 55 tumors were totally resected, 1 patient 
was subtotally resected at first operation and totally resected in a second operation. 18 
patients were scheduled for alkylating chemotherapy, 16 patients were treated with 
radiotherapy and 11 patients underwent both radiotherapy and alkylating 
chemotherapy. No adjuvant therapy was applied in 30 patients (Tab 3).  
 
Tab 3. Treatment protocols in 65 patients 
For 12 patients a possible adjuvant therapy is unknown 
 
One patient was treated by polychemotherapy with a CCNU and methotrexate (MTX) 
protocol:MTX was given by intrathecal application, a TMZ protocol was used in 3 
patients; a MeCCNU protocol was accepted in 2 patients; 8 patients were chosen for 
CCNU chemotherapy and in 4 patients the correct chemotherapy regimen could not 
be identified. In total 18 patients received chemotherapy including alkylating agents. 
Treatment Radiotherapy No radiotherapy total 
Chemotherapy 11（20.8%） 7（13.2%） 18 
No chemotherapy 5（9.4%） 30（56.6%） 35 
Total 16 37 53 
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16 patients underwent fractionated spinal radiotherapy with 30-54 Gy (1.8-2 Gy/day). 
Among them, 2 recurrent patients received radiotherapy after the second operation. 37 
patients had no radiotherapy. 53 patients were followed up in detail; there are still 12 
patients which were lost in follow up. The time of follow up varied from 1 month to 
175 months, mean 54.6 months. It was terminated until to death for any reason or to 
the last date of follow-up. The overall survival (OS) from 1 month to 175 months, 
mean 54.6 months， and PFS varied from 1 month to 145 months, mean 46.1 months. 
There was only one serious complication during the radiotherapy and chemotherapy 
with one female patient, who suffered radiation myelitis followed by paraplegia 
rapidly 1.5 months after radiotherapy. 
 
Tab 4. Expressions of MGMT,Ku80, and Ki67 analyzed by One-way ANOVA method 
Variables    MGMT (mean±SD)    MGMT 95% CI   pvalue      KU80(mean±SD)  KU8095%  pvalue     ki67（mean±SD)   Ki67 95% CI  
pvalue 
Overall      44.6±33.6     36.3-56.9               59.0±29.3    51.8-66.3              7.2±11.7     4.3-10.0 
Sex(n) 
M(n=23)    34.7±28.8     22.3-47.2               60.5±26.7    49.0-72.1               6.2±6.7       3.3-9.1 
Ｆ(n=42)    49.9±35.0     39.0-60.7    0.065     58.2±31.0   48.6-67.8  0.761        7.7±13.7      3.4-11.9  0.632 
Age 
< 50(n=48)   48.8±34.4    38.9-58.7              57.9±29.0  49.6-66.2              7.9±12.6      4.3-11.5 
≥ 50(n=17)   31.6±28.0    16.7-46.5     0.05     62.5±31.1  .9-79.0   0.594     4.9±8.3       0.5-9.3   0.390 
Tumor site 
MO(n=5)   35.7±20.8      9.9-61.5              78.4±6.7    70.3-86.7              14.4±11.4     3.9-24.4 
C(n=18)    40.6±37.5      21.9-59.2              53.5±34.1    36.6-70.5              11.4±19.6     1.6-21.1   
T(n=22)    39.7±32.3     25.5-54.0              58.1±30.3    44.6-71.5              5.3 ±6.0      2.6-7.9 
L(n=20)    55.7±33.0      40.2-71.2    0.358     60.2±26.5    47.8-72.6   0.420     3.7±4.0       1.8-5.6  0.089 
Surg. Type    
TR(n=56)   44.5±34.2      35.3-53.6             61.2±28.1    53.6-68.7             7.3±12.4      3.9-10.6 
SR（n=9）  45.2±30.8     21.5-68.8    0.955    45.8±34.9   19.0-72.6   0.146       6.7±6.1       1.8-11.2  0.85 
Diagnosis                                                                                                        
Grade: 
GraI(n=13)   42.2±33.8      28.8-69.7            60.8 ±29.3 43.1-78.5               2.4±3.3  3.9-4.4 (1,3) 0.000  
GraII(n=35)  46.3±34.4      34.5-58.1             63.4 ±25.8  54.5-72.2               2.9±3.0  1.9-4.0 (1,4) 0.009 
GraIII(n=5)    38.1±27.1      4.3-71.7              15.4±5.6    8.4-22.3               15.4±5.6 8.5-22.4(2,3) 0.007 
GraIV(n=12)   37.2±35.4      14.7-59.6         0.779     47.7±37.3   24.0-71.4   0.407    21.1±20.4 8.2-34.1(2,4) 0.000 
                                                                                                                 Total sig:  0.000 
Group: 
Ependymoma and astrocytoma (glioblastoma):                                                                           
E (n=47)      46.9±34.5       36.7-57.0            62.1±27.8   54.0-70.2              3.0±3.3   2.0-4.0 
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A (n=18)      36.8±31.2       23.1-54.1        0.377    51.0±32.6   34.8-67.2 0.176      17.9±17.7 9.2-26.7  0.000 
Subgroup: 
 E(I,II,n=46)    46.8±34.4    36.6-57.0           62.7±26.7   54.8-70.6             2.7±3.0  1.8-3.6（1,2） 0.002 
E(III,IV,n=2)  44.0±40.0    -311.7-399.7        36.1±51.1   -422.6-49.48          9.9±0.1 8.6-11.2（1,3）0.168 
A(I,II,n=2)    54.2±29.7    -212.6-52.9         62.0±31.1   -217.5-341.5          5.7±1.0  3.2-14.6（1,4）0.002 
A(III.IV,n=15) 36.5 ±32.8    36.3-52.9         0.745   50.4±34.5   51.8-66.3     0.361    20.7±4.7 10.6-30.7（2,3) 0.099 
                                                                                                                   （2,4）0.426 
                                                                                                                     （3,4）0.274 
                                                                                                                 Total sig: 0.000 
Chemotherapy(A)                                                                                                    
Yes(n=18)   39.6±31.3      24.0-55.2             60.0±32.1   44.1-76.0           10.8±8.7   6.5-15.1 
No(n=35)   43.0±33.7      30.9-55.2        0.452     60.1±27.9   50.5-69.7   0.994    7.1±14.2   2.3-12.0    0.235 
Radiotherapy 
Yes(n=16)   39.4±31.7      22.5±56.5           58.2±31.7   41.3-75.1            15.7±18.4  5.9-25.5 
No(n=37)    46.7±34.5      35.2±58.2          0.471           60.9±28.3   51.4-73.3    0.758    5.2±7.4    2.8-7.7     0.004 
Both CT and RT 
Yes(n=11)   37.2±28.0      18.4±56.0            60.3±32.7   38.8-82.2            13.0±7.2   8.2-17.8 
No(n=30)   47.5±34.3      34.6-60.3        0.379     61.2±27.6   50.9-71.5    0.931    4.7±6.7    2.2-7.2     0.001 
Metastases 
Yes(n=5)    20.0±28.0      -14.7-54.7             38.0±38.4   -9.7-85.9            20.0±9.5   8.1-31.8 
No(n=54)    49.3±33.3      40.2-58.4        0.063      61.3±27.8   53.7-68.9   0.088     6.3±11.8   3.0±9.5   0.015 
Unk(n=6) 
Relapse       
Yes(n=23)   35.1±33.1     20.8-49.5              50.5±34.0   35.8-65.2              12.4±17.1   5.0-19.8 
No(n=40)    50.8±33.5     40.1-61.5        0.078      63.9±25.7   55.7-72.1       0.111         4.4±5.8     2.5-6.2   0.038 
Unk(n=2)  
KPS 
KPS ≥80(n=23)48.9±32.5    34.8-62.9              58.5±27.2    46.8-70.3             5.8±6.9    2.8-8.8 
KPS＜80(n=29) 41.3±33.7    28.5-54.1        0.417      62.8±32.9    50.3-75.3       0.620       7.6±8.5    4.4-10.8    0.410 
Unk(n=13) 
PFS 
PFS≥60Mon(n=18)43.3±32.2          27.3-59.3              67.3±18.2     58.3-76.4    (1,2) 0.08   3.1±5.2    0.5-5.7 
PFS<60Mon(n=17) 42.3±35.9         23.9-60.8             40.5 ±33.7    23.2-57.8    (1,3) 0.900  7.3±7.8    3.3-11.3  
PFS<24Mon(n=28) 48.7±34.1         35.5-61.9       0.792     66.4±28.1     55.5-77.3    (2,3) 0.013         9.8±15.8  3.7-16.0  0.166 
Unk(n=2)                                                                                Total sig:  0.005 
D/S 
S(n=38)      45.5±32.3     34.9-56.2            65.4±26.5      56.7-74.1               4.7±5.9   2.8-6.6 
D(n=12)      34.0±32.2     13.6-54.4     0.286    48.3±38.4      23.9-72.8       0.089      14.3±9.1  8.5-20.1    0.004 
Unk(n=15) 
MGMT expression 
Low(n=35)   16.6±13.6      11.9-21.3            57.5±32.0     46.5-68.5             7.5±8.6    4.6-10.4 
High(n=30)   77.2±15.0      71.6-82.8     0.000     60.8±26.3     51.0-70.6       0.658     6.7±14.6   1.3-12.2    0.793 
Ku80 expression 
Low(n=22)   44.0±32.9       29.5-58.6            23.2±18.6     14.9-31.4             9.4±17.9   1.5-17.4 
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Hight(n=43) 44.8±34.3       34.3-55.4 0.930      77.4±10.9     74.0-80.7    0.000      6.0±6.5    4.0-8.0     0.390 
Ki67 expression 
Low(n=49)   49.2±33.1       39.7-58.7            62.1±25.6    54.7-69.4            2.6±2.5    1.9-3.3 
Hight(n=16) 30.5 ±31.8      13.5±47.4       0.05     49.7±38.1    29.4-70.0    0.237     21.1±17.0  12.1-30.1   0.001  
Abbreviations: M, male;  F, female;  MO, medulla oblongata;  C, cervical myelon; T, thoracic 
myelon; L, lumbar myelon; D, died; S, survived ; Grad, grade; E,ependymoma;A, astrocytoma, 
CT, chemotherapy; RT, radiotherapy; RC, radio-chemotherapy; Mon, month; Unk, unknown; CI, 
confidence interval; SD, standard deviation; Surg, surgery; PFS, progression free survival;KPS, 
Karnofsky 
3.2 MGMT expression in spinal glioma 
The level of MGMT expression was determined by MGMT immunohistochemistry in 
65 spinal glioma tissues. The absolute expression levels of MGMT in all groups 
classified according to variables were analyzed by One-way ANOVA method and 
listed in Table 4. There is a considerable variability in MGMT expression level 
ranging between 0% and 98.6% in spinal glioma (mean 44.56%).  
We found that there was not statistically significant difference of the expression of 
MGMT in spinal gliomas (table4), that included sex, tumor site, surgical type, tumor 
grade and treatment protocol. But, for the variable age, we could find a significant 
difference of the expression of MGMT between patients of age< 50 years subgroup 
and the age≥50 years subgroup (P=0.05). Some similar results were obtained from 
variables of metastases group (P=0.063), relapse group (P=0.078). 
35 tumor samples (54%) demonstrated a low MGMT staining (positive rate < 50%, 
mean 16.6%) (Fig 1-4), and 30 (46%) tumor samples demonstrated intermediate and 
high MGMT expression (positive rate ≥50%, mean 77.2%)(Fig 5,6). The MGMT 
expression level in spinal glioma (N = 65) was neither correlated with age of the 
patient nor with diagnosis. (There was not significant difference in MGMT expression 
between different gender (P=0.179) and histological diagnosis (P=0.475). The 
differences in MGMT expression between patients less than 50 years and older than 
50 years reached statistical significance (P=0.044). This revealed that the MGMT 
level in age≥50 years patients is usually lower than in patients whose age is less than 
50 years.  
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Fig 1 .MGMT  staining  ×200 (0%) 
 
 
Fig 2 .  MGMT  staining  ×400  (0%) 
 
 
Fig 3 . MGMT staining  ×200 (3.0%) 
 
 
Fig 4 . MGMT staining  ×400 (3.0%) 
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Fig 5. MGMT staining  ×200 (90.6%) 
 
 
Fig 6. MGMT staining  ×400 (90.6%) 
Fig. 1~6   Representative photomicrographs showing immunostaining for MGMT in spinal 
glioma samples. Fig 1, 2（glioblastoma IV）Immunohistochemistrical staining demonstrates the 
negative expression of MGMT in the spinal glioma tissue, and low cytoplasmic staining (3.0%) 
can be observed in Fig 3,4 (ependymoma II), and high cytoplasmic staining (90.6%) can be 
observed in Fig 5, 6 (ependymoma II).  
Tab 5. Baseline patient characteristics and MGMT expression 
Study, n (%) MGMT（weak） MGMT（strong） p value 
Sex    
Male(n=23) 15（23.1%） 8（12.3%）  
Female（n=42） 20（30.8%） 22（33.9%） 0.179 
Age     
< 50 years(n=48) 23（35.4%） 25（38.5%）  
≥ 50 years(n=17) 12（18.5%） 5（7.75%） 0.044 
Diagnosis    
Ependymoma(n=47) 24（36.9%） 23（35.4%）  
Astrocytoma(GBM)（n=18） 11（16.9%） 7（10.8%） 0.475 
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3.3 Ku80 expression in spinal glioma 
The level of Ku80 expression was determined by Ku80 immunohistochemistry in 65 
spinal glioma tissues. The absolute expression levels of Ku80 in all groups classified 
according to variables were analyzed by One-way ANOVA method and listed in Table 
4. There is a considerable variability in expression level ranging between 0% and 
97.0% in spinal glioma (mean 59.2%). There are no statistical significant differences 
of the Ku80 expression in spinal gliomas among most of variables analyzed including 
sex, age, tumor site, surgical type, tumor grade and treatment protocol. For the PFS 
group, we could find a statistical significant difference of the expression of Ku80 
between patients in PFS< 60 months subgroup and in PFS≥60 months subgroup 
(P=0.005). Otherwise, there is significant difference in the expression of Ku80 
between patients that suffered metastases and those who were free of metastases 
(P=0.088), although it did not reach statistical significance. Similar results were found 
in the death/survival group (P=0.089). 
The results of the Ku80 expression for the age, gender, diagnosis subgroups are 
presented in Table 6. 22 tumor samples (33.9%) demonstrated low Ku80 staining 
(positive rate < 50%，mean 23.2%±18.6%) (Fig 7-10), and 43 (69.1%) tumor 
samples demonstrated high Ku80 expression (positive rate ≥ 50%，mean 77.4%±
10.9%) (Fig 11-14).  
The Ku80 expression level in spinal gliomas (N = 65) could not be correlated with 
gender, age and diagnosis of the patient. A significant difference in Ku80 expression 
could not be found between gender (P=0.673), age (P=0.804) and histological 
subgroups (P=0.271)(Tab 6). 
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Tab 6. Baseline patient characteristics and Ku80 expression 
Study, n (%) Ku80（low） Ku80（high） p value 
Sex    
Male(n=23) 7（10.8%） 16（24.6%）  
Female（n=42） 15（23.1%） 27（41.5%） 0.673 
Age     
< 50 years(n=48) 17（26.2%） 31（47.7%）  
≥ 50 years(n=17) 5（7.7%） 12（18.5%） 0.804 
Diagnosis    
Ependymoma(n=47) 8（12.3%） 39（60.0%）  
Astrocytoma(GBM)（n=18） 14（21.5%） 4（6.23%） 0.271 
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Fig 7. Ku80 staining  ×200 (0%) 
 
 
Fig 8. Ku80 staining  ×400 (0%) 
 
 
Fig 9. Ku80 staining  ×200 (37.2%) 
 
 
Fig 10. Ku80  staining  ×400 (37.2%) 
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Fig 11. Ku80 staining  ×200 (73.0%) 
 
 
Fi12. Ku80 staining  ×400 (73.0%) 
 
 
Fig 13. Ku80 staining  ×200 (91.6%) 
 
 
Fig.14. Ku80 staining  ×400 (91.6%) 
Fig. 7~14 Representative photomicrographs showing immunostaining for Ku80 in spinal glioma 
samples. Fig 7, 8 (ependymoma III) Immunohistochemical staining demonstrating the negative 
expression of Ku80 in the spinal glioma tissue. Low nuclear staining (37.2%) could be observed in 
Fig 9, 10 (astrocytoma III). Strong nuclear staining (73.0%) could be observed in Fig 11,12 
(astrocytoma III). Very strong nuclear staining (91.6%) could be observed in Fig 13,14 
(ependymoma II). 
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3.4 Ki67 expression in spinal glioma 
The Ki67 expression was determined by Ki67 immunohistochemistry in 65 spinal 
glioma tissues. A considerable variability in Ki67 expression level was found  
ranging between 0% and 80.0% in spinal gliomas (mean 7.15%). The absolute 
expression level of Ki67 in all groups classified according to variables were analyzed 
by One-way ANOVA method and listed in Table 4. There is statistical significant 
difference of the expression of Ki67 between patients in death/survival (D/S) group 
(P=0.004). Similar results were found for the relapse group (P=0.038), the metastases 
group (P=0.015), the group receive both or not radiotherapy and chemotherapy 
(P=0.001), radiotherapy group (P=0.004), histological diagnosis (including grades, 
ependymoma and astrocytoma) groups (P=0.000). 
There are not statistically significant differences for the expression of Ki67 in spinal 
gliomas, for the sex, age, tumor site, surgical type (Table 4). 
The results about Ki67 expression of age, gender, diagnosis are presented in Table 7. 
49 tumor samples (75%) demonstrated low Ki67 staining (positive rate < 10%，mean 
2.6%±2.5%) (Fig 15, 16), and 16 (25%) tumor samples demonstrated high Ki67 
expression (positive rate ≥ 10%，mean 21.1%±17.0%) (Fig 17-20). The Ki67 
expression level in spinal glioma (N = 65) could not be correlated with gender and 
age of patients. A significant difference in Ki67 expression could not be found 
between gender (P=0.842) and age (P=0.538). But the differences in Ki67 expression 
between the histogical diagnoses (ependymoma and astrocytoma (including GBM,)) 
reached statistical significance (P=0.001): The Ki67 level in patients with 
ependymoma is usually lower than in patients who suffered astrocytoma (including 
GBM). 
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Tab 7. Baseline patient characteristics and Ki67 expression 
Study, n (%) Ki67（low） Ki67（high） p value 
Sex    
Male(n=23) 17（26.2%） 6（9.2%）  
Female（n=42） 32（49.2%） 10（15.4%） 0.842 
Age     
< 50 years(n=48) 36（55.4%） 12（18.5%）  
≥ 50 years(n=17) 13（20.0%） 4（6.2%） 0.538 
Diagnosis    
Ependymoma(n=47) 42（64.6%） 5（7.7%）  
Astrocytoma(GBM)（n=18） 7（21.5%） 11（16.9%） 0.001 
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Fig 15. Ki67 staining  ×200 (0%) 
 
 
Fig 16. Ki67 staining  ×400 (0%) 
 
 
Fig 17. Ki67 staining  ×200 (29.0%) 
 
 
Fig 18. Ki67 staining  x400 (29.0%) 
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Fig 19. Ki67 staining  ×200 (80.0%) 
 
 
Fig 20. Ki67 staining  ×400 (80.0%) 
Fig. 15~20   Representative photomicrographs showing immunostaining for Ki67 in spinal 
glioma samples. Fig 15, 16 (ependymoma I) Immunohistochemical staining demonstrating the 
negative expression of Ki67 in the spinal glioma tissue. High nuclear staining (29.0%) could be 
observed in Fig 17, 18 (glioblastoma IV). A very high nuclear staining (80.0%) could be observed 
in Fig 19, 20 (gliblastoma IV).  
 
3.5 Relevance analysis between MGMT expression and Ki67 expression 
Strong positivity of MGMT staining was observed in 30 (46%) of 65 spinal glioma 
cases and strong Ki67 expression was found in 16 (25%) patients. Among 65 cases 
that were interpretable for high expression each proteins, only 4 cases (6%) showed 
high expression for both MGMT and Ki67, 26 cases (40.0%) showed high expression 
only for MGMT, 12 cases (19%) showed high expression only for Ki67, and 23 cases 
(35%) showed low expression for both proteins (Tab 8). 
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Tab. 8 Correlation between MGMT expression and Ki67 expression 
                                                                    Sig: 0.853 
 
Ki67 high expression could be statistically significantly correlated with tumor 
recurrence (P=0.038), tumor grade (P=0.000)), D/S (P=0.004), metastases (P=0.015) 
(Tab 4). We could find that patients have a strong trend toward that poor prognosis in 
MGMT low expression but Ki67 high expression, as compared with MGMT high 
expression and Ki67 low expression cases (Tab 4, Tab 8). Ki67 expression was 
statistical significant correlated with OS (r=-0.283, P=0.024), tumor recurrence 
(r=-0.242, P=0.038), tumor grade (r=-0.415, P=0.001) and tumor subgroups (r=0.569, 
P=0.000) (Tab 9). There is also a statistically significant difference observed between 
levels in MGMT expression and Ki67 expression (P=0.05, Tab 4; r=-0.24, P=0.05, 
Tab9). There were only 5 patients with a negative MGMT expression and a very high 
Ki67 expression in our study group (MGMT: 0%). All of them were spinal 
glioblastomas (gradeIV). We could find that MGMT and Ki67 have significant 
negative correlation. Litter co-expression of MGMT and Ki67 exists in patients with 
spinal glioma (6.2%, Tab 8). 
 
 
 
 
 
 
 
 
Protein Ki67 (low) Ki67 (high) Total 
MGMT (low) 23 (35.4%) 12 (18.5%) 35 
MGMT (high) 26 (40.0%) 4 (6.2%) 30 
Total 49 16 65 
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Tab. 9    The correlations among variables 
 
   
PFS  OS D/S CT  RT  Ki67 MGMT Ku80 RE   G  SG 
PFS P.C(2-tailed) 1 .857** -.255* 0.036 0.041 -0.237 -0.096 0.091 .403** -.304* -.279* 
  Sig(2-tailed) 0 0.044 0.779 0.75 0.061 0.455 0.477 0.001 0.015 0.027 
  N 63 63 63 63 63 63 63 63 63 63 63 
OS P.C(2-tailed) .857** 1 -0.133 0.162 0.085 -.283* -0.166 0.122 0.155 -.317* -.304* 
  Sig(2-tailed) 0   0.299 0.206 0.506 0.024 0.195 0.341 0.225 0.011 0.015 
  N 63 63 63 63 63 63 63 63 63 63 63 
D/S P.C(2-tailed) -.255* -0.133 1 .481** .498** -0.058 0.06 -.266* -.295* 0.057 0.086 
  Sig(2-tailed) 0.044 0.299   0 0 0.649 0.635 0.033 0.017 0.654 0.495 
  N 63 63 65 65 65 65 65 65 65 65 65 
CT P.C(2-tailed) 0.036 0.162 .481** 1 .770** -.364** 0.014 -0.083 0.104 -.343** -.363** 
  Sig(2-tailed) 0.779 0.206 0   0 0.003 0.91 0.511 0.408 0.005 0.003 
  N 63 63 65 65 65 65 65 65 65 65 65 
RT P.C(2-tailed) 0.041 0.085 .498** .770** 1 -.493** 0.04 -0.117 0.165 -.415** -.437** 
  Sig(2-tailed) 0.75 0.506 0 0   0 0.752 0.353 0.189 0.001 0 
  N 63 63 65 65 65 65 65 65 65 65 65 
Ki67 P.C(2-tailed) -0.237 -.283* -0.058 -.364** -.493** 1 -0.242 -0.12 -.258* .524** .569** 
  Sig(2-tailed) 0.061 0.024 0.649 0.003 0   0.052 0.343 0.038 0 0 
  N 63 63 65 65 65 65 65 65 65 65 65 
MGMT P.C(2-tailed) -0.096 -0.166 0.06 0.014 0.04 -0.242 1 0.01 0.099 -0.09 -0.06 
  Sig(2-tailed) 0.455 0.195 0.635 0.91 0.752 0.052   0.937 0.434 0.475 0.634 
  N 63 63 65 65 65 65 65 65 65 65 65 
Ku80 P.C(2-tailed) 0.091 0.122 -.266* -0.083 -0.117 -0.12 0.01 1 0.116 -0.139 -0.093 
  Sig(2-tailed) 0.477 0.341 0.033 0.511 0.353 0.343 0.937   0.357 0.271 0.459 
  N 63 63 65 65 65 65 65 65 65 65 65 
RE P.C(2-tailed) .403** 0.155 -.295* 0.104 0.165 -.258* 0.099 0.116 1 -.467** -.442** 
  Sig(2-tailed) 0.001 0.225 0.017 0.408 0.189 0.038 0.434 0.357   0 0 
  N 63 63 65 65 65 65 65 65 65 65 65 
G P.C(2-tailed) -.304* -.317* 0.057 -.343** -.415** .524** -0.09 -0.139 -.467** 1 .960** 
  Sig(2-tailed) 0.015 0.011 0.654 0.005 0.001 0 0.475 0.271 0   0 
  N 63 63 65 65 65 65 65 65 65 65 65 
SG P.C(2-tailed) -.279* -.304* 0.086 -.363** -.437** .569** -0.06 -0.093 -.442** .960** 1 
  Sig(2-tailed) 0.027 0.015 0.495 0.003 0 0 0.634 0.459 0 0   
  N 63 63 65 65 65 65 65 65 65 65 65 
 Abbreviations ：PFS, progress free survival; OS, overall survival; S, survival; D, death; CT, chemotherapy; 
RT, radiotherapy; RE, recurrence; G, Group; SG, subgroup; PC, Pearson Correlation; N, Number. 
*.* Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed) 
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3.6 Relevance analysis between Ku80 expression and Ki67 expression 
Strong positivity of Ku80 staining was observed in 43 (66.2%) of 65 spinal glioma 
cases and strong Ki67 expression was found in 16 (24.7%) patients. Among 65 cases 
that were interpretable for both proteins, there are 9 cases (13.9%) with a high 
expression for both Ku80 and Ki67, 34 cases (52.3%) with a high expression only for 
Ku80, 7 cases (10.8%) with a high expression only for Ki67, and 15 cases (23.1%) 
with a low expression for both proteins (Tab. 10). There is no significant difference 
observed between levels in Ku80 expression and Ki67 expression (P=0.237, Tab. 4), 
and it seems, there is not significant correlation was found between levels in Ku80 
expression and Ki67 expression too.  
However, we also found a phenomenon with only 6 patients showing a negative Ku80 
expression (0%) in our study group. 5 of them are spinal glioblastomas (grade IV) and 
the other one is ependymoma (grade III). As documented previously, there are only 11 
glioblastomas and 2 ependymomas (Grade III) in our study group altogether (Tab. 1)  
All of them showed a high Ki67 expression. Moreover there were only 3 patients with 
both a negative MGMT and Ku80 staining (0%) in our study group. They were all 
glioblastomas. 
Otherwise, we found that there was significant difference in Ku80 expression between 
PFS ≥60Mon and PFS<60Mon (P=0.08). These differences revealed that the low 
expression level of Ku80 is usually accompanied high expression of Ki67 and with 
poor PFS.  
Tab 10. Correlation between Ku80 expression and Ki67 expression 
                                                                      Sig: 0.262 
Location Protein Ki67 (low) Ki67 (high)  Total 
Ku80 (low)  15 (23%)   7 (11%)  22 
Ku80 (high) 34 (52%) 9 (14%) 43 
Total 49 16 65 
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3.7 Relevance analysis among others variables 
We used the Bivariate Correlations method to calculate the relevance among variables in 
this study. The significance of the correlations in variables and Pearson correlation was 
calculated. The relevance of patients were analyzed for progress free survival (PFS), 
overall survival (OS), death/survival (D/S)，chemotherapy (CT), radiotherapy (RT), 
MGMT, Ku80, Ki67, recurrence (RE), tumor group (G), and subgroup (SG). Through the 
bivariate correlations analysis among variables (Tab 9) we could find that OS (P=0.000), 
D/S (P=0.044), RE (P=0.001), G (P=0.015), SG (P=0.027) were significant related with 
PFS in spinal glioma；Ki67 (P=0.024), G (P=0.011), SG (P=0.015) were significantly 
related with OS in spinal glioma; CT (P=0.000), RT (P=0.000), Ku80 (P=0.033) and RE 
(P=0.017) were significant related with OS (Tab 9). Additionally, we could find, that PFS 
(P=0.001), OS (P=0.017) , Ki67 (P=0.038) , G (P=0.000) and SG (0.000) were statistical 
significant related with tumor relapse (RE) in spinal glioma. Radiotherapy (RT) (r=0.165, 
P=0.189) could not be shown to be correlated. But in our study group only 16 patients 
received radiotherapy. 14 patients received radiotherapy after initial diagnosis and the 
first operation. 2 patients received radiotherapy after tumor recurrence and second 
operation. Of these 16 patients, 11 patients are still in remission. This group included 2 
grade I tumors, 4 grade II, 4 grade III and 1 grade IV. 2 recurrent tumors are still 
progression free (113 months and 31 month). As high grade tumor usually received 
radiotherapy and are prone to relapse, there was not statistical significant correlation 
between tumor recurrence and radiotherapy in our study group compared to the low 
grade tumor group. 
Similar reasons maybe also adapt for the correlation of chemotherapy and tumor relapse. 
Otherwise, there are 11 patients received adjuvant both chemotherapy and radiotherapy. 
So the correlation between tumor recurrence and chemotherapy (alkylating agents) also 
was more complicated for the clinical result in our study group. We found both 
chemotherapy and radiotherapy have definitely effects not only for initial diagnosis 
spinal glioma but also for recurrent spinal glioma. 
 
3.8 Some variables regarding recurrence of spinal glioma 
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We used the Chi-square test for different variables regarding recurrence of spinal tumors 
in this study. The significance of the Chi-square test in variables was calculated. The 
variables of patients were analyzed including surgical type, chemotherapy, radiotherapy. 
In table 11, we show that there is statistical significant difference observed for tumor 
recurrence with tumor total removed and tumor subtotal removed (P=0.016). Similar 
results were obtained for patients for spinal glioma grade (I+II) receiving radiotherapy or 
not (P =0.013), and receiving chemotherapy or not in the same group (P =0.002). 
However, there was no statistical significant difference obtained for tumor relapsed in 
spinal glioma grade (III+IV) receiving radiotherapy or not (P =0.056), and received 
chemotherapy or not (P =0.056). Nonetheless, there is a near statistically significant 
difference. We could show that surgical type (P=0.016), radiotherapy for spinal glioma 
grade (I+II) (P=0.013) and chemotherapy for grade (I+II) could be significantly 
correlated with tumor recurrence and prognosis in spinal glioma (Tab 11). 
 
Tab 11. Chi-square test for different variables regarding recurrence of spinal tumors 
Variables  Recurrence   No Recurrence p value 
Surgical type    
Total remove 16 38  
Subtotal remove 7 2 0.016 
Radiotherapy 
grade (I+II) 
   
Yes 0 6  
No 5 27 0.013 
   grade (III+IV) 
Yes               
No 
 
6 
7 
                
4 
0 
 
 
0.056 
chemotherapy 
grade (I+II) 
   
Yes 1 7  
No 4 24 0.002 
grade (III+IV)    
Yes 6 4  
No 7 0 0.056 
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3.9 Some variables regarding metastasis of spinal glioma 
We used the Chi-square test for different variables and their influence on metastasis 
formation of spinal tumors in our study. The significance of the Chi-square test in 
variables also was calculated. The different variables of patients were analyzed including 
diagnosis and its subgroups, the low and high expression of MGMT, Ku80 and Ki67. We 
could find a statistical significant difference observed among spinal glioma grade I, II, III, 
IV (P=0.002, Tab 12). Similar results were obtained for ependymomas and astrocytomas 
(P=0.000, Tab 12) and the low and high expression of Ki67 (P=0.005, Tab 12). However, 
there was no statistical significant difference obtained for the influence on metastasis 
formation of spinal tumors between the low and high expression of MGMT (P=0.212, 
Tab 12) and Ku80 (P=0.155, Tab12). 
 
Tab12. Chi-square test for variables and their influence on metastasis formation 
Variables  Metastasis       No metastasis p value 
Diagnosis    
Grade I 0 12  
Grade II 0 31  
Grade III 1 4  
Grade IV 4 8 0.002 
Ependymoma 0 42  
Astrocytoma 5 13 0.000 
MGMT    
     Low 4 28  
High 1 27 0.212 
Ku80    
     Low 3 16  
     High 2 39 0.155 
Ki67    
     Low 1 43  
High 4 12 0.005 
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3.10 Survival analysis in spinal glioma 
We used the Kaplan-Meier method to calculate the survival rates for this study. The 
significance of the difference in the survival curves was calculated with the log-rank tests. 
Kaplan-Meier survival curves of patients were analyzed according to sex, age, tumor 
location, surgical approach, treatment protocol, alkylating agents, and the expression of 
MGMT, Ku80 and Ki67. Tumor locations divided into four groups stated as above: the 
tumors located mainly in medulla oblongata, the tumors located mainly in cervical 
myelon, tumors located mainly in thoracic myelon and located mainly in lumbar myelon. 
Treatment protocol was categorized into four groups described as above: chemotherapy, 
radiotherapy, radiochemotherapy and no adjuvant therapy. These patients also classified 
into alkylating agents group and non- alkylating agents group, radiotherapy group and 
non-radiotherapy group and both alkylating agents and radiotherapy group and non- both 
alkylating agents and radiotherapy group. The surgical type was categorized into tumor 
total removed and tumor subtotal removed.The expression of MGMT, Ku80 and Ki67 
was evaluated by immunohistochemistry staining, those patients were divided into low 
expression group (positive rate is less than 50% in MGMT, Ku80 and positive rate is less 
than 10% in Ki67) and high expression group (positive rate is not less than 50% in 
MGMT, Ku80 and positive rate is not less than 10% in Ki67).  
Progression-free survival and overall survival were estimated by the Kaplan–Meier 
method and compared with the use of the log-rank test. Kaplan-Meier analysis between 
variables with OS revealed that patients with tumors located mainly in cervical myelon, 
thoracic myelon and lumbar myelon had statistically significantly longer median survival 
time (MST) than patients with tumors located mainly in medulla oblongata (MST: 124.4 
months, 140.5 months, 127.1 months vs. 17.8 months; P =0.004; log-rank test). Similar 
results were obtained between tumor total remove and subtotal remove group (MST: 
147.5months vs. 27.7 months; P =0.000, log-rank test), patients who received 
radiochemotherapy and no radiochemotherapy treatment protocol (only for grade III and 
grade IV patients) (MST: 77.2 vs. months, 16.7; P =0.002; log-rank test; Tab 13). This 
result supports the conclusions that alkylating agents and radiotherapy play an important 
role in treatment of patients with grade III and grade IV spinal glioma patients. Also 
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surgical resection, tumor location are related with OS prognosis in spinal glioma. 
Significantly statistically different results were obtained for patients who had high vs. 
low Ki67 expression (MST: 52.4 vs.157.2 months P =0.000, log-rank test). Different 
results were obtained for patients who had high and low MGMT expression (MST: 110.4 
months vs. 138.7months; P =0.895, log-rank test) and high and low Ku80 expression 
(MST: 144.9 months vs. 127.0 months; P =0.424, log-rank test), these differences did not 
reach statistical significance. Similar results were obtained for male and female patients 
(P =0.406, log-rank test), patients of the < 50 years and ≥ 50 years group (P =0.275, 
log-rank test). For the radiotherapy group and alkylating group, overall survival of 
patients who received these therapies was shorter than who not received these protocols. 
This is due to the poorer WHO tumor grade in this group (grade III and grade IV glioma). 
Results obtained for patients who grade I and II receiving both alkylating agents and 
radiotherapy or not group showed no positive effect for low grade tumors (P =0.457). 
Kaplan-Meier analysis between variables with PFS revealed the almost same statistical 
results as OS (Tab 14). We could show that surgical type (P=0.000), 
radiochemotherapeutic treatment protocol (P=0.000) and Ki67 (P=0.010) were 
significantly related with PFS prognosis in spinal glioma (Tab 14).  
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Tab13. Kaplan–Meier analyses for the correlation between variables and OS 
Variables OS Mean 95% CI p value 
Sex    
Male 126.3 90.2-162.4  
Female 146.2 125.0-167.3 0.406 
Age    
< 50 years 127.5 101.7-153.2  
≥ 50 years 159.1 130.7-187.6 0.275 
Tumor location    
MO 17.8 9.9-25.6  
C 124.4 83.5-165.2  
T 140.5 111.8-169.2  
L+S 127.1 112．2-141.9 0.004 
Surgical type    
Total remove 147.5 128.9-165.9  
Subtotal remove 27.7 17.6-37.9 0.000 
Treatment protocol(grade III +IV)   
Radiochemotherapy 77.2 34.1-120.3  
No Radiochemotherapy 16.7 6.6-26.7 0.002 
Treatment protocol (grade I+II)    
Chemotherapy 40.8 5.5-76.1  
Radiotherapy 88.2 56.4-120.1  
Radiochemotherapy 69.8 1.9-128.3  
No treatment 74.4 49.4-99.4 0.457 
Alkylating agents    
yes 88.7 58.3-119.0  
No 144.0 121.9-166.2 0.220 
Radiotherapy    
Yes 108.6 83.4-133.8  
No 136.9 112.3-161.6 0.908 
Both alkylating agents and radiotherapy  
yes 85.7 47.3-124.2  
no 142.7 121.5-164.0 0.184 
MGMT expression    
Low 138.7 113.3-164.1  
High 110.4 92.19-128.6 0.895 
Ku80 expression    
Low 127.0 92.2-161.8  
High 144.9 123.6-166.3 0.424 
Ki67 expression    
Low 157.2 140.9-173.5  
High 52.4 32.8-71.9 0.000 
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Tab14. Kaplan–Meier analyses for the correlation between variables and PFS 
Variables PFS Mean 95% CI p value 
Sex    
Male 113.9 76.3-151.5  
Female 102.9 74.9-131.0 0.298 
Age    
< 50 years 92.4 63.3-121.6  
≥ 50 years 137．0 99.9-175.7 0.167 
Tumor location    
MO 12.3 7.0-17.5  
C 81.8 37.3-126.4  
T 114.8 79.9-149.8  
L+S 102.9 76.2-129.8 0.097 
Surgical type    
Total remove 114.9 90.6-139.3  
Subtotal remove 15.3 6.6-29.0 0.000 
Treatment protocol (grade III+IV)    
Radiochemotherapy 59.0 25.9-92.1  
No Radiochemotherapy 7.5 4.6-10.4 0.000 
Treatment protocol (grade I+II)    
Chemotherapy 34.0 2.3-65.7  
Radiotherapy 55.8 20.6-91.0  
Radiochemotherapy 62.5 0.8-124.2  
No treatment 65.1 41.7-88.5 0.511 
MGMT expression    
Low 102.6 73.2-132.0  
High 90.2 66.4-114.0 0.488 
Ku80 expression    
Low 90.4 50.5-130.0  
High 114.7 86.5-142.8 0.267 
Ki67 expression    
Low 122.3 96.6-147.9  
High 43.8 24.4-63.2 0.010 
 
 
In the same time, we also analyzed the influences of MGMT, Ku80 on PFS and OS on 
using alkylating agents and radiotherapy between different subgroups (Tab 15). There 
we could show that patients with high expression of MGMT had a statistical 
significantly longer median PFS than patients with low expression MGMT (108.0 
months vs. 46.4 months; P =0.038; log-rank test) in the alkylating agent group. 
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Significantly different results were obtained for patients in the no-alkylating agents 
subgroup (132.48 months vs. 87.68 months; P =0.082, log-rank test), radiotherapy 
subgroup for Ku80 (68.8 months vs. 31.4 months; P =0.510, log-rank test) and the no 
radiotherapy subgroup for Ku80 (140.4 months vs. 90.6 months; P =0.153, log-rank 
test). These differences did not reach statistical significance. Although the expression 
of MGMT and Ku80 varies in spinal glioma, high expression of MGMT and Ku80 
maybe have correlation with longer PFS in the spinal glioma.  
 
Tab 15. Influence of MGMT, Ku80 on PFS and OS between different subgroups 
Subgroup Variables OS Mean     p value  PFS Mean p value  
Alkylating agents (n=18) 
MGMT Low (n=10) 65.9 
 
46.4 
 
MGMT High (n=8) 114.1         0.448      108.0     0.038    
No alkylating agents (n=35) 
MGMT Low (n=10) 120.3 87.68 
MGMT High (n=25) 141.7         0.651 132.48    0.082 
Radiotherapy (n=16) 
Ku80 Low (n=5) 56.0 
 
31.4 
 
Ku80 High (n=11) 138.7         0.196 68.8      0.510 
No Radiotherapy (n=37) 
 
Ku80 Low (n=11) 106.3 94.6 
Ku80 High (n=26) 156.8         0.571 140.4     0.153 
 
We could show that patients with high expression Ki67 had a statistical significantly 
shorter median PFS than patients who with low expression Ki67 (43.8 months vs 
122.3 months; P =0.010; log-rank test). Similar results were also obtained for the 
MST (48.4months vs. 85.6months; P =0.115; log-rank test), although this difference 
did not reach statistical significance. Ki67 (P=0.010) was also related with PFS 
prognosis in spinal glioma. 
 
Tab 16.  The influences of the expression Ki67 on PFS and OS 
Group Variables OS Mean (Mon)   p value PFS Mean (Mon) p value 
1 Ki67<10%(n=47) 157.2  122.3  
2 Ki67≥10%(n=16) 52.4 0.000 43.8 0.010 
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4. Discussion 
As primary spinal cord gliomas are rare, there has not been paid sufficient attention 
especially for its unsatisfactory therapy. There is no consensus regarding the 
management of spinal glioma. Nowadays spinal glioma remains incurable in a party 
of patients. Surgery, radiation therapy, and chemotherapy have been used in various 
combinations; however, the extent of resection and the use of adjuvant chemotherapy, 
radiation therapy and the prevention of tumor recurrence and the treatment for tumor 
relapse are not clearly associated with a survival advantage. (Jallo GI, 2003). Which 
group or subgroup of spinal gliomas tends to relapse and needs radiotherapy, 
chemotherapy or both radiochemotherapy? Which chemotherapeutic agents are most 
effective in the treatment of spinal glioma? A better insight into its biology may be 
crucial to answer these questions and to improve the prognosis of spinal glioma. 
Special attention has been paid in recent years to identifying prognostic factors related 
to the molecular biological characteristics of the tumor, in an attempt to improve the 
effective treatment and the prognosis (Richard AR, 2007). This study was aimed at 
detecting the expression of MGMT, Ku80 and Ki67 on spinal glioma by 
immunohistochemistry (IHC) staining to evaluate the relationship between MGMT, 
Ku80 and Ki67 expression level to clinical characteristics and outcomes, thus 
determine whether these immunophenotypes were prognostic markers in spinal 
glioma and could be a guide to chose an optimal and reasonable individualized 
treatment.  
 
4.1 MGMT expression level in spinal glioma 
Many studies concerning MGMT expression, including IHC studies, have been 
performed in cerebral gliomas and other tumors. Most association analyses between 
MGMT and glioma were performed in brain glioma, especially for the subgroup of 
glioblastomas. The MGMT status in spinal glioma is still unclear. Only one case 
report in the literature correlating MGMT expression with the clinical response of a 
high-grade spinal cord astrocytoma treated using TMZ, suggesting a clinical value of 
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MGMT evaluation in treatment benefit from alkylating agents in spinal glioma patient. 
The expression of MGMT protein tested by IHC is also not reported for spinal glioma 
in the literature.  
O6-methylguanine- DNA-methyl-transferase (MGMT) is an enzyme in the DNA 
repair process that specifically removes cytotoxic O6-alkylguanine adducts, thus 
mediating resistance to alkylating agents. This DNA repair enzyme plays a role in 
maintaining the integrity of the DNA in normal cells but also protects tumor cells 
against alkylating and methylating chemotherapeutic agents, resulting in drug 
resistance. It is therefore assumed that the good prognosis of brain glioma with low 
MGMT expression was caused by a better response to alkylating agents such as 
fotemustine, which a cytotoxic agent belonging to the nitrosurea family. It has been 
observed that MGMT gene expression seems to be related to the methylation of the 
MGMT promoter, MGMT enzyme activity, protein expression and cell resistance to 
anti-tumor alkylating agents could predict a possible chemosensitivity (Kaina B, 
2007). Therefore the study of MGMT status could be of therapeutic and prognostic 
interest.  
In our study, the level of MGMT expression was detected by IHC method in 65 spinal 
glioma tissues. 30 (46.2%) tumor samples demonstrated intermediate and high 
MGMT expression respectively. There are no significant differences in MGMT 
expression level with patients’ gender, locations of tumors, group and sub group of 
diagnosis, PFS, D/S. But for the age group, we could find a significant difference of 
the expression of MGMT between patients in age< 50 years subgroup and in age≥50 
years subgroup reaching statistical significance (P=0.044). This revealed, that the 
MGMT level in age≥50 years patients is usually lower than in patients with a age 
less than 50 years. 
For the metastases group, we could find a difference of the expression of MGMT 
between metastases group and no metastases group (P=0.063), although it did not 
reach a statistical significant difference. Some similar results were obtained from 
variables of relapse group (P=0.078), and Ki67 expression group (0.05). For the Ki67 
high expression statistical significant correlation with malignant and benign of spinal 
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gliomas, we found that there is a strong trend that poor prognosis in MGMT low 
expression but Ki67 high expression patients, as compared with MGMT high 
expression but Ki67 low expression cases. This trend is also discovered for the Ki67 
expression with a statistical significant correlation with OS, tumor recurrence, tumor 
grade, and tumor subgroup of patients. Although there is no statistical significant 
difference observed between levels in MGMT expression and Ki67 expression 
(P=0.051, Tab 4; r=-0.24, P=0.052). Otherwise, there are only 5 patients with a 
negative MGMT expression. Otherwisw Ki67 expression was very high in our study 
group (MGMT: 0%) with all of them being spinal glioblastomas (grade IV) except 
one anaplastic ependymoma. We could show that MGMT and Ki67 have significant 
negative correlation.  
No significant difference on overall survival between patients who had high MGMT 
expression and patients with low MGMT expression was observed by Kaplan-Meier 
method (P =0.895, log-rank test). Similar results were observed for PFS (P=0.488). So, 
in this study, MGMT protein expression can not be considered as a definite predictor 
to chemotherapeutic (alkylating) response and prognosis in patients with spinal 
glioma.  
We used the Bivariate Correlations method to calculate the relevance among variables 
in this study, the significance of the correlations in variables and Pearson correlation 
was calculated. Surprisingly,we could show that patients who underwent 
chemotherapy (alkylating agents) had significantly longer MST than patients who did 
not underwent chemotherapy (alkylating agents) (P =0.000). This supported the 
conclusion that alkylating agents play an important role in chemotherapy outcomes in 
patients with spinal glioma. There are three possible explanations to this surprising 
results: a, this phenomenon is caused by the error of analysis techniques, it may be 
one way to choose adequate method or combine with other methods such as 
methylation specific PCR for preferable assessing the MGMT status; b, sample size is 
not enough, further analysis with larger number of cases is necessary to clarify the 
utility of MGMT immunohistochemistry as a predictor of therapy of spinal glioma; c, 
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There are 11 patients received adjuvant both chemotherapy and radiotherapy in our 
study group, given alkylating agents prescribed as part of radiochemotherapy 
regimens, so that the correlation between tumor recurrence and chemotherapy 
(alkylating agents) also become more complicated. Both the alkylating agents and 
radiotherapy maybe play a role on tumor cells. 
 
4.2 Ku80 expression level in spinal glioma and outcome.  
As a DNA repair protein, Ku80 forms a heterodimer with Ku70, called Ku that binds 
to DNA ends, nicks, gaps, and hairpins. In vitro, Ku forms a complex called 
DNA-dependent protein kinase (DNA-PK) by associating with a 450-kDa catalytic 
subunit, DNA-PKcs (Ute Moll et al, 1999). Cells mutated by the deletion of any of 
these genes are hypersensitive to ionizing radiation. An absence of Ku80 results in an 
increased sensitivity to ionizing radiation. Although most cancerous tissues were 
consistently positive for Ku80 (Moll U, 1999), and radiotherapy is also an important 
component of multimodal treatment for many malignant brain and spinal gliomas in 
clinic, the research efforts on Ku80 with CNS glioma are rare. It is reported that 
hypersensitivity of Ku80-deficient cell lines to DNA damage is correlated with the 
effects of ionizing radiation on growth and development of cerebral glioma cell lines 
(Takashi O, 2004; Dhandapani KM, 2007; He F, 2007; Holcomb VB, 2006). Other 
than these studies performed with established glioblastoma cell lines, no other is 
known about Ku80 expression in brain glioma. So far, the expression and significance 
of Ku80 in spinal glioma has not been analyzed. 
The level of Ku80 expression was determined by Ku80 immunohistochemistry in 65 
spinal glioma tissues. There is variability in expression level ranging between 0% and 
97.0% in our study group. There are no statistical significant differences of the 
expression of Ku80 in spinal gliomas between sex, age, tumor site, surgical type, 
tumor grade and treatment protocol. But, for the PSF group, we found a statistical 
significant difference for the expression of Ku80 in PFS< 60 months subgroup and in 
PFS≥60 months subgroup (P=0.005). Otherwise, there is a difference of the 
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expression of Ku80 for patients that suffered metastases and metastases free subgroup 
(P=0.088), although it did not reach a statistical significant difference. Similar result 
was found in death/survival group (P=0.089). FKu80 expression has usually the 
highest levels in normal neurons and glial cells of the central nervous system (Moll U, 
1999). Low expression of Ku80 maybe has a correlation with the degree of 
malignance of spinal glioma. 
No significant difference on overall survival between patients who had high Ku80 
expression and patients with low Ku80 expression was observed by Kaplan-Meier 
method (P =0.424, log-rank test) with similar results observed for PFS (P=0.267). So 
it is difficult to considere Ku80 protein expression as a definite predictor for 
radiotherapy response and prognosis in patients with spinal glioma.  
Although it is supported that Ku protein expression is correlated with radiation 
treatment outcome (Friesland SL, 2003; Harima YS, 2003; ), there are exceptions. 
Some stated that Ku80 expression is not correlated with radiation sensitivity 
(Kasten-Pisula US, 2008). In our group, the Bivariate Correlations showed that 
patients who underwent radiotherapy, had significantly longer MST than patients with 
no radiotherapy (P=0.000). 2 recurrent tumors even did not progress so far (113 
months and 31 month). Among 16 patients with radiotherapy in our group, 4 patients 
with recurrent spinal glioblastomas recurrent died and 1 patient was lost to follow up. 
The other 11 patients are still progression free. This also supports the conclusion that 
radiotherapy plays an important role on OS in patients with spinal glioma, although 
their Ku80 protein expression has not definite correlated with radiation sensitivity. 
 
4.3 Ki67 expression level in spinal glioma and outcome, Ki67 maybe a prognostic 
marker of spinal glioma.  
Several studies show the Ki67 index in intracranial glioma as a reproducible and 
robust prognostic factor (Burger PC, 1986; Haapasalo A, 2005; Vaishali SS, 2004; 
Rushing EJ, 1981; Suzuki S, 2001; Verstegen MJ, 2002). Verstegen showed for 
intracranial ependymoma a significant correlation of a low Ki67 index with a 
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favorable patient outcome. The Ki67 tumor cell proliferation index is an independent 
prognostic factor in ependymoma patients (Verstegen MJ, 2002); Haapasalo looked at 
Ki67 in different grades of astrocytic and found that Ki67 is expressed in proliferating 
astrocytoma nuclei, which are scarce in low grade tumours and abundant in 
glioblastoma (Haapasalo A, 2005). Although many studies looked at brain gliomas 
and showed the expression and significance of Ki67, there is few literature about Ki67 
expression in spinal glioma so far.  
The Ki67 expression in 65 spinal glioma tissues is found to be of a considerable 
variability ranging between 0% and 80.0% (mean 7.15%). 49 tumor samples (75.4%) 
had a low Ki67 staining (positive rate < 10%，mean 2.6%±2.5%), and 16 (24.6%) 
tumor samples showed a high Ki67 expression (positive rate ≥ 10%，mean 21.1%±
17.0%). The absolute expression level of Ki67 in all groups classified according to 
variables analyzed by One-way ANOVA method showed that no statistical significant 
differences of the expression of Ki67 in spinal gliomas in sex, age, tumor site and for 
the surgical therapy groups. But there are statistical significant differences of the 
expression of Ki67 for patients concerning the death/survival(D/S) groups (P=0.004), 
relapse groups (P=0.038), metastases groups (P=0.015), both or no radiotherapy and 
chemotherapy groups (P=0.001), the radiotherapy group (P=0.004) and the diagnosis 
groups (P=0.000, P=0.002). There are also statistical significant difference on overall 
survival between patients who had high Ki67 expression and patients with low Ki67 
expression observed by Kaplan-Meier method (P=0.000, log-rank test) and for PFS 
(P=0.010). We could show that most spinal gliomas (75.4%) with low expression of 
Ki67 are low grade gliomas; the tumors with high expression of Ki67 are significantly 
correlated to malignant tumors. This relates with poor prognosis including poor D/S, 
OS and PFS. They tend to relapse earlier and are prone form metastases. The 
prognosis of astrocytoma is poorer than that of ependymoma. We could identify Ki67 
as a prognostic marker of spinal glioma.  
The proliferation activity of tumors can be assessed by means of Ki67 
immunohistochemistry, which is now widely used in clinical pathology and 
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neuropathology diagnostics. Consistent with our results, Burger and co-workers could 
show the tight association between Ki-67 immunopositivity and glioma grade in 
freshly frozen samples of cranial astrocytomas (Burger PC, 1986). Others also have 
described the prognostic value of immunostaining with MIB-1（Ki67） (Onda K, 1994; 
Cunningham JM, 1997). Based on a large number of studies, the added prognostic 
information provided by Ki-67 immunostaining is now well established with regard to 
astrocytic tumors of the brain. The latest WHO classification of central nervous 
system tumors (WHO Classification of Tumors of the Central Nervous System, 3rd 
Edition) includes Ki67 as an additional tool in histological typing and grading, 
although it cannot be regarded as being entirely prognostic in individual cases.  
Haapasalo also used ultrarapid Ki67 immunostaining in frozen section interpretation 
of gliomas for intraoperative guidance of the resection (Haapasalo, 2005). With this 
work we can confirm this correlation of Ki67 expression for spinal gliomas.  
 
4.4 Relevance analysis between MGMT expression and Ki67 expression 
In our study patients with a high Ki67 expression were associated with a low MGMT 
expression and reduced survival in Kaplan-Meier analysis. A strong trend was found 
that toward poor prognosis in patients with high Ki67 expression but low MGMT 
expression, as compared with low Ki67 expression but high MGMT expression cases. 
There is significant difference observed between the levels in MGMT expression and 
Ki67 expression (P=0.05). Furthermore, we found that the expressions of MGMT and 
Ki67 statistically correlated (r=-0.24, P=0.05). All 5 patients with negative MGMT 
expression showed very high Ki67 expression in our study group (MGMT: 0%), and 
all of them were spinal glioblastomas (grade IV). It indicates that MGMT and Ki67 
have significant opposite correlation. 
MGMT is DNA repair gene, which plays an important role of protecting tumor cells 
against DNA injuries caused by chemotherapy (alkylating agents). High expression of 
MGMT can lead to a failure of alkylating chemotherapy due to a tumor cell resistance 
to DNA damage impacted by these drugs. In most case, it has been shown that those 
tumors with abundance of MGMT protein were resistant to alkylating 
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chemotherapeutics, while those with low MGMT activity were sensitive to alkylating 
agents. MGMT behaves as a potential predictor of response to chemotherapy and also 
maybe a prognostic biomarker of spinal glioma just the same as Ki67. Given MGMT 
is one of the most important factors determining drug resistance to alkylation, some 
strategies have been developed to inhibit MGMT expression in tumors with the aid of 
MGMT inhibitors, and further enhance the anti-neoplastic efficiency of alkylating 
agents. (Krishnan M et al, 2007) 
 
4.5 Relevance analysis between Ku80 expression and Ki67 expression 
No significant difference was observed between the levels of Ku80 and Ki67 
expression analyzed by One-way ANOVA in our study(P=0.237). A correlation was 
also not found for these two proteins (r=-0.12, P=0.343). However, we found a 
phenomenon of 6 patients with negative Ku80 expression (0%) and 5 of them being 
spinal glioblastomas (grade IV) and the other one an ependymoma (grade III). Overall 
there were only 11 glioblastomas and 2 ependymomas (grade III) in our study group - 
all of them with a high Ki67. Moreover there were 3 patients with both MGMT and 
Ku80 negative (0%) in our study group, all of them being glioblastomas. It could 
indicate that near half of the spinal glioblastoma with MGMT and/or Ku80 expression 
could be radiosensitive and/or chemosensitive (alkylating agents). We found there is 
not a statistical significant difference in Ku80 expression between PFS ≥60Mon and 
PFS<60Mon (P=0.08). These differences revealed that the low expression level of 
Ku80 is usually accompanied by a high expression of Ki67 resulting in a poor PFS. 
As an important repair gene of DSBs Ku80 potential prognostic marker for the 
prediction of radiotherapy outcome and also a prognostic biomarker for spinal glioma 
just like Ki67. 
 4.6 Relevance analysis between treatment protocols and tumor recurrence. 
Operation type, radiotherapy and chemotherapy may be prognostic markers for 
relapse in spinal glioma. 
As spinal gliomas are rare tumors, there is no consensus regarding the management of 
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malignant spinal cord glioma. Surgery, radiation therapy, and chemotherapy have 
been used in various combinations; however, the extent of resection and use of 
adjuvant chemotherapy or radiation therapy are not clearly associated with a survival 
advantage (Jallo GI, 2003).  
We used the Chi-square test to analyze the treatment protocols regarding recurrence of 
spinal tumors in this study. The variables of patients were analyzed including surgical 
type, chemotherapy and radiotherapy. We could demonstrate statistical significant 
difference regarding tumor recurrence with total versus subtotal removal of the tumor 
(P=0.016). Similar results were obtained for patients with benign spinal glioma (grade 
I+II) that received radiotherapy versus not (P =0.013), and received chemotherapy or 
not in the same group (P =0.002). Although without statistical significance we found a 
difference in tumor recurrence for patients with malignant spinal glioma (grade III+IV) 
that received radiotherapy versus not (P =0.056), and that received chemotherapy 
versus not (P=0.056). 
Thus we could show, that radical tumor resection (P=0.016), radiotherapy for benign 
spinal glioma (grade I+II) (P=0.013) and chemotherapy for benign tumors (grade I+II) 
improved the rate of PFS statistically significantly. 
With the advent of microsurgery and MRI, especially, using of MRI had dramatically 
improved the anatomical understanding of the surgical pathology, and the use of 
intraoperative neurophysiological monitoring has tremendously increased the 
understanding of the functional integrity of the spinal cord pathways during surgery 
and in the process of neurological recovery thereafter. Nevertheless, differences of 
opinion still exist about patients suffering from an intramedullary tumor and their 
optimal individualized treatment. In spite of the advances in surgical treatment, the 
old concept of ‘biopsy and radiation’ is apparently not extinct (O’Sullivan C, 1994; 
Houten JK, 2000), especially in some developing areas of the world. It has been stated, 
that a total or near-total resection is the best treatment for spinal gliomas (Kothbauer 
K, 2007). Our result can confirm this statement for spinal glioma with statistical 
significant results. 
Despite lack of consensus, surgery followed by radiation therapy, especially for 
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incompletely resected lesions and recurrent tumors, is a common treatment paradigm. 
Several studies indicate that the use of postoperative radiation therapy modestly 
improves both local control and survival in spinal cord ependymomas and 
astrocytomas. Modern treatment planning and imaging allow more accurate target 
definition respecting the related normal tissue tolerances (Isaacson SR, 2000; 
Minehan KJ, 1995; Houten JK, 2000). Furthermore we found that radiotherapy has 
significant effects on PFS not only for initialy treated but also recurrent spinal glioma.  
Several centers have treated the malignant spinal gliomas with multimodal treatment 
including chemotherapy (Allen JC, 1998). Concerning benign spinal gliomas, only 
recurrent patients have been treated with chemotherapy (TMZ) demonstrating only 
modest efficacy with acceptable toxicity in 22 patients (Chamberlain MC, 2008). 
Our study indicate that with the guide of molecular prognostic factors (e.g. MGMT, 
Ki67) there might be a base for adjuvant chemotherapy (Taylor MD, 2005; Richard A 
R, 2007).   
  
4.7 Relevance variables regarding metastasis of spinal glioma 
5 patients (8%) suffered tumor metastases in our study group. Analyzed by One-way 
ANOVA, there is statistical significant difference for the occurrence of metastases for 
high versus low Ki67 expression (P=0.015); although not statistical significant the 
metastases formation with high versus low MGMT expression (P=0.065), Ku80 
expression (P=0.088) was obvious different. We also used the Chi-square test for 
different variables and their influence on metastasis formation of spinal tumors in our 
study. It showed a statistical significant difference observed for the different WHO 
grades (P=0.002). Similar results were obtained for ependymomas versus 
astrocytomas (P=0.000) and for low versus high expression of Ki67 (P=0.005). 
Thus, we could show that WHO grades (P=0.002), histology (P=0.000) and the 
expression of Ki67 (P=0.005) significantly influenced the formation of metastases; 
the expression of MGMT (P=0.065) and Ku80 (P=0.088) probably influences the 
formation of metastasis. 
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4.8 Prognostic factors in spinal glioma 
There is no consensus regarding treatment with most part of glioma (Richard AR, 
2007). Prognostic factors are important not only for the discrimination of patients 
with spinal glioma into specific risk groups and for the identification and assessment 
of appropriate therapies on an individually base, but also for comparing results of 
clinical trials and planing those. However, it is difficult to identify prognostic factors 
in series from single institutions because of the limited number of cases. Rudà could 
show for intracranial and spinal ependymomas that a complete resection should be 
achieved whenever possible at first surgery or at reoperation. Involved field 
radiotherapy is recommended for anaplastic or incompletely resected grade II tumors 
(Rudà R, 2008). Craniospinal irradiation is reserved for metastatic disease (Rudà R, 
2008). Chemotherapy is not advocated as primary treatment, but it is best utilized as 
salvage treatment for patients failing surgery and radiotherapy (Rudà R, 2008). 
In our survival analysis, the expression of Ki67, extent of resection, radiotherapy, and 
chemotherapy were considered important predictors, whereas MGMT and Ku80 
expression were not statistically significant. Nonetheless, we found, that MGMT and 
Ku80 also are potential prognostic markers in tumor recurrence, metastasis and for 
choosing adjuvant therapy. 
Additonally ，when the tumor involved regions like the medulla oblongata and 
cervical myelon ,that was associated with a poorer prognosis than that tumors of the 
thoracal myelon or the lumbar region.  
5. Conclusion 
The expression of MGMT, Ku80 and Ki67 was observed in the majority of spinal 
glioma. It is the first time to detect the expression of MGMT, Ku80 and Ki67 proteins 
in spinal glioma with immunohistochemistry method. Ki67 was predictive for 
survival in this study. MGMT and Ku80 are potential prognostic factor for patients 
with spinal glioma. In addition to extent of tumor resection, radiotherapy, 
chemotherapy (alkylating agents) and tumor location correlated significantly with 
PFS and OS. The role of these variables and the clinical relevance deserves to be 
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assessed in further studies. 
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6. Summary 
Compared to cranial gliomas, the spinal cord glioma is a rare tumor of the central 
nervous system. Due to its infrequent incidence, there is no consensus regarding the 
management of spinal cord glioma until nowadays. Radical surgery, radiation therapy, 
and chemotherapy have been used in various combinations around the world; so far 
the extent of resection and the use of adjuvant chemotherapy or radiotherapy have not 
been clearly shown to be associated with a survival advantage. MGMT is one of the 
most important genetic factors determining drug resistance while Ku80 determining 
radiosensitivity, and Ki67 determining tumor proliferation. The expression of MGMT, 
Ku80 and Ki67 in spinal glioma remains unclear. If they interfere with the 
chemosensitivity, radiosensitivity and with the prognosis of spinal glioma, an 
optimized therapeutic protocol might be found based on these molecular factors. The 
aim of our study was to detect the expression of MGMT, Ku80 and Ki67 on spinal 
glioma by immunohistochemistry staining and to assess the relationship between 
MGMT and Ki67, and Ku80 and Ki67 expression level and clinical outcomes, thus 
determine whether these immunophenotypes were prognostic factors in spinal glioma. 
At the same time we evaluated the efficacy of surgery, radiotherapy and 
chemotherapy efficacy in a series of spinal gliomas through the retrospective analysis.  
65 patients with spinal glioma from Germany and China were included in this 
retrospective study. All tissues were reviewed and diagnosed with H.E staining by a 
neuropathologist. The expression of MGMT, Ku80 and Ki67 in tumor samples was 
determined by immunohistochemistry using the MGMT, Ku80 and Ki67 monoclonal 
mouse antihuman antibody. One thousand neoplastic cells per specimen were 
counted. On the basis of the percentages of positive cells in the tumors, these tumors 
were defined as low MGMT expression or low Ku80 expression when there were 
fewer than 50% positive cells, and high expression when positive rate was more than 
50%. A low Ki67 expression was defined as less than 10% positive cells and a high 
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expression when the positive rate was more than 10%. Analyses were performed with 
the use of SPSS 17.0. 
The mean expression level of MGMT, Ku80 and Ki67 in 65 spinal gliomas was 
44.6%±33.6%, 59.0%±29.3% and 7.2%±11.7%. resp. A correlation was found 
between MGMT and Ki67 proteins expressions (r=-0.242, P=0.052). A significant 
difference in MGMT expression could be found between age<50 years old group and 
age≥50 years old group (P=0.05). Differences in Ku80 and MGMT expression 
between primary and recurrent spinal gliomas did not reach significance (P>0.05).  
Kaplan-Meier analysis revealed that patients with tumors showing a high Ki67 
expression had significantly shorter progress free survival (PFS) than patients who 
had low Ki67 expression (122.3 months vs. 43.8 months; P =0.010). Expression of 
Ki67, extent of resection, radiotherapy, chemotherapy were related with prognosis in 
spinal glioma (P<0.05), whereas MGMT and Ku80 expression were not statistically 
significant, but showed to be potentially related to tumor recurrence and metastases 
formation (MGMT (P=0.065) and Ku80 (P=0.088)).  
This study showed that the expression of MGMT, Ku80 and Ki67 could be observed 
in the majority of spinal gliomas. It is the first time to detect the expression of MGMT, 
Ku80 and Ki67 proteins in spinal glioma with immunohistochemistry staining method, 
Ki67 even predicting survival in this study. In addition to, Ki67 and other clinical 
variables including tumor location, extent of resection, radiotherapy, chemotherapy 
are correlated significantly with OS and PFS. 
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CT               Chemotherapy 
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DNA              Deoxyribonucleic acid 
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GBM             Glioblastoma multiforme 
GLA             Gamma-linolenic acid 
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RE               Recurrence 
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